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Mild Traumatic Brain Injury (mTBI) has been described as a ‘silent epidemic’ 
and is a significant health burden to the global population.  New Zealand 
specific data estimates mTBI to occur 749 in 100,000 person-years.  While the 
majority of patients that suffer mTBI make a complete recovery between 3 and 
12 months following the injury, approximately 15% of all mTBI will have 
ongoing symptoms one year after initial injury.  This condition is known as 
Post Concussion Syndrome (PCS). 
 
The sheer scale and cost of PCS, not just in terms of acute care and 
rehabilitation costs, but the emotional and financial costs to the patient and 
their family are significant; this makes injury prevention, detection and care a 
significant health priority.  At present, no robust or reliable radiological or 
biochemical markers have been developed to diagnose mTBI.  Moving forward, 
injury prevention, early diagnosis, treatment and identification of people at risk 
of developing PCS would mean better patient education and resource 
allocation for rehabilitation; this in turn may ease the burden of this condition. 
 
The objective with this thesis is to identify potential brain differences 
associated with full or poor recovery post mTBI and to determine whether 
differences existed with a group of participants with chronic pain and a group 
of healthy controls. 
 
Methods	
This study used both structural (grey matter volume and cortical thickness) 
and DTI techniques to investigate the brains of participants who had 
experienced an mTBI and two control groups.  Data previously collected from 
138 participants were used for this study; forty-two subjects comprised the PCS 
group.  Thirty subjects deemed fully recovered from mTBI comprised the non-
PCS group.  The two control groups were healthy controls (n=41) and those 
with a chronic pain condition (CP; n=25).  The PCS, non-PCS and CP groups 
were all matched for age, gender, education, injury, severity and pre-injury 
	 ii	




There were no significant differences in brain volume, cortical thickness, or DTI 
metrics along the centres of principal white matter tracts between the PCS and 
non-PCS groups, nor when these two mTBI groups were compared to controls.  
However, the CP participants exhibited reduced cerebellar grey matter volume 
relative to all three groups (PCS, non-PCS, and healthy controls) and significant 
reduction in FA and increased MD in several white matter tracts; there were no 
cortical thickness differences between any of the groups. 
 
Conclusion	
Overall the heterogeneity of the literature help to frame my results within the 
larger field.  Lack of significant differences is not an uncommon finding.  In my 
hands, PCS and non-PCS were indistinguishable on T1-weighted images, as 
well as DTI.  A prospective study following mTBI from acute to chronic state 
with serial imaging or other study techniques such as HARDI or diffusion 
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ACC  Accident Compensation Corporation 
ADC  Apparent Diffusion Coefficient 
ADP  Adenosine Diphosphate 
ANOVA Analysis of Variance 
ATP  Adenosine Triphosphate 
BBB   Blood Brain Barrier 
CBT  Cognitive Behavioral Therapy  
CP  Chronic Pain 
CSF  Cerebral Spinal Fluid 
CT   Computed Tomography 
CTE  Chronic Trauma Encephalopathy 
CWIT  Colour Word Interference Test 
D  Diffusion Coefficient 
DAI   Diffuse Axonal Injury 
DSM IV Diagnostic and Statistical Manual of Mental Disorders 4th Edition 
DTI  Diffusion Tensor Imaging 
EEG  Electroencephalogram 
ED   Emergency Department 
FA  Fractional anisotropy  
FDR  False discovery rate 
fMRI  Functional MRI 
FSL  FMRIB Software 
FWE  Family-wise error rate 
GM  Grey matter  
GP   General Practitioner 
HADS  Hospital Anxiety and Depression scale (Anxiety or Depression)  
IASP  International Association for the Study of Pain  
ICD-10 International Classification of Disease, 10th Revision 
ICV  Intracranial Volume  
IL-1   Interleukin-1 
LOC  Loss of consciousness 
MD  Mean diffusivity 
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MDT  Multidisciplinary team 
MEG  Magnetoencephalography 
MR  Magnetic Resonance 
MRI  Magnetic Resonance Imaging 
mTBI  Mild Traumatic Brain Injury 
NGF  Nerve Growth Factor 
NMV  Net Magnetisation Vector 
Non-PCS Non Post-Concussion Syndrome 
NZBRI New Zealand Brain Research Institute 
PCS  Post-Concussion Syndrome 
PET  Positron Emission Tomography 
PTA  Post Traumatic Amnesia  
PTSD  Post-traumatic Stress Disorder 
RBANS TS Repeatable Battery Assessment of Neuropsychological Status 
Total Score 
RF  Radiofrequency 
ROI  Region of Interest 
RPQ  Rivermead Post-Concussion Symptom Questionnaire  
ROS  Reactive oxygen species 
SPECT Single Positron Emission Computed Tomography 
SPM12 Statistical Parametric Mapping 12  
SSH  Starship Hospital 
SSRI  Selective Serotonin Reuptake Inhibiters 
T  Tesla  
TBSS  Tract Based Spatial Statistics 
TNF   Tumour Necrosis Factor a 
VBM  Voxel Based Morphometry 
WM  White matter 




Traumatic brain injury (TBI) is defined as an alteration in brain function caused 
by an external force (1)(2).  Clinical criteria are used to characterize TBI patients 
by severity into mild, moderate or severe TBI subsets.  There is much variation 
and heterogeneity in the published literature as to what defines each of these 
terms.  Several definitions of mild traumatic brain injury (mTBI) have been 
suggested.  For the purpose of this study, the definition of mTBI will be that 
used by the ACC Evidence Based best practice guideline on TBI (2).  This is to 
ensure consistency because the mTBI participants in this study have been 
recruited from the ACC Concussion clinic, which also uses the ACC definition 
of mTBI. 
 
The clinical criteria used to determine severity of TBI are: presenting level of 
consciousness measured on the Glasgow Coma Scale (GCS), duration of loss of 
consciousness (LOC) and post traumatic amnesia (PTA) (2)(3).  The GCS was 
developed by Teasdale and Jennett and published in 1974 as a tool for the 
neurological assessment of coma and impaired consciousness (4).  There are 
three aspects of behavior assessed: eyes, verbal and motor, and then a 
cumulative score given out of 15 (range 3-15).  This scale is simple, 
reproducible and widely used in the routine medical observations performed 
by medical professionals.  The PTA duration is used in conjunction with the 
GCS to define severity of TBI.  PTA is any amnesia or memory loss 
(anterograde or retrograde) from the time of injury.  The duration a patient 
experiences PTA is used in the injury classification (Table 1.1). 
	
Table	1-1		The	definition	of	severity	of	TBI	
 LOC GCS PTA 
Mild <30 minutes 13-15 0-1 day 
Moderate 30minutes-24hours 8-12 1-7 days 
Severe >24 hours 3-8 >7 days 
LOC=Loss	of	consciousness,	GCS=Glasgow	Coma	Scale,	PTA=Post	traumatic	amnesia.		Modified	from	(2)(6)(7) 
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It is also important to acknowledge that other factors that may influence 
consciousness level are excluded, such as drug and alcohol use, medical drug 
sedation or other organ injury.  These may artificially cause a reduced GCS 
unrelated to the TBI (2)(5).  This is also why the GCS is not the sole measure of 
severity in TBI.  Of note the other main definitions referenced are by the Mild 
Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special 
Interest Group of the American Congress of Rehabilitation Medicine 1993 (6), 
the WHO Collaborating Centre Task Force on mTBI 2004 (7), and the Position 
Statement by the Demographics and Clinical Assessment Working Group of 
the International and Interagency Initiative toward Common Data Elements for 
Research in TBI and Psychological Health 2010 (1). 
 
The American Congress of Rehabilitation Medicine define a patient with mTBI 
as  
“a person who has had a traumatically induced physiological disruption 
of brain function, as manifested by at least one of the following;  
1. Any period of loss of consciousness;  
2. Any loss of memory for events immediately before or after the accident;  
3. Any alteration in mental state at the time of the accident (e.g feeling 
dazed, disoriented, or confused); and  
4. Focal neurological deficit(s) that may or may not be transient, but 
where the severity of injury does not exceed the following: 
• LOC of approximately 30 minutes or less; 
• After 30 minutes, an initial GCS 13-15; and 
• PTA not greater than 24 hours.” (6) 
 
The WHO task force describes mTBI as  
“an acute brain injury resulting from mechanical energy to the 
head from external physical forces.  Operational criteria for 
clinical identification include;  
(i) 1 or more of the following: confusion or disorientation, 
loss of consciousness for 30 minutes or less, PTA for less 
than 24 hours, and/or other transient neurological 
abnormalities such as focal signs, seizure, and intracranial 
lesion not requiring surgery;  
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(ii) GCS of 13-15 after 30 minutes post-injury or later upon 
presentation for healthcare.   
These manifestations of mTBI must not be due to drugs, alcohol, 
medications, caused by other injuries or treatment for other 
injuries (e.g. systemic injuries, facial injuries or intubation), 
caused by other problems (e.g. psychological trauma, language 
barrier or coexisting medical conditions) or caused by 
penetrating craniocerebral injury” (7). 
 
The Common Data Elements working group proposed the following definition: 
“TBI is defined as an alteration in brain function, or other evidence of brain 
pathology, caused by an external force.”  In the explanatory notes it does 
describe the alteration in brain function and any period of LOC, PTA, 
neurological deficits and any alteration in mental state at the time of injury.  
However, this definition does lack precision in defining the terms of each 
component (1).  
 
The terms mTBI, head injury and concussion are often used interchangeably.  
mTBI is the preferred term as it more accurately encompasses the brain 
dysfunction following trauma (8).  At present mTBI is very much in the 
spotlight, both in mainstream media and published literature.  This is no doubt 
due to the recent advances in the identification and diagnosis of Chronic 
Traumatic Encephalopathy (CTE) (9)(10)(11), with huge investment in research 
by professional sports leagues (12) and by the military, with specific interest in 
combat injuries (13)(14)(15).  In New Zealand the new concussion guidelines in 




TBI is a significant health burden to the global population and a significant 
cause of morbidity and mortality in all age groups.  In fact it has been 
suggested that TBI is a ‘silent epidemic’ (17) and this can be illustrated by the 
WHO estimating that by 2020 TBI will become the leading cause of death and 
disability (18).  Using internationally published data and extrapolating, the 
estimated incidence of mTBI is 100-300 per 100,000 population.  However 
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taking into account not all mTBI is treated in the hospital setting, and hence not 
all cases are reported, the true rate is estimated to be closer to 600 per 100,000 
(19).  It is estimated that as many as 10 million people globally are affected 
annually by TBI (18). 
 
A 2010-2011 New Zealand population-based incidence study using hospital, 
general practice and Accident Compensation Corporation (ACC) data in the 
Waikato region estimated mTBI to occur in 749 per 100,000 person-years (20).  
From this it is estimated there are 35,000 head injuries in New Zealand per year 
(21).  In the year July 2015 to July 2016, ACC had 13,811 new claims for 
concussion/brain injury and had 17,913 active cases during this period.  The 
total cost of all ACC payments was more than $85 million dollars over this 
period (22).  This includes both acute treatment costs and rehabilitation. 
 
ACC figures from 2003 similarly showed that 61.9% of people with mTBI were 
male (2).  The young and the old are also over represented.  ACC statistics 
show that the incidence of mTBI peaks in the 15-19 and over-60 years-old age 
groups, with the highest rates occurring in the 15-19 years age group (2).  A 
Waikato population based study of 2010 again found similar results with those 
aged 15-34 years representing 40% of all mTBI cases.  Males were again over 
represented with almost twice the rates of mTBI (RR 1.73) in females.  This 
New Zealand data mirrors similar findings in overseas data; there is a clear 
male, young and old predominance (3)(5)(23). 
 
In New Zealand the leading causes of TBI are: falls 38%, mechanical forces 21%, 
motor vehicle accident (MVA) 20% and assaults 17% (20) (Table 1.2).  
Mechanism of injury patterns are similar in reported literature from around the 
world (3)(23).  One difference, however, is that in countries with a high 
socioeconomic status, motor vehicle accidents involve automobile passengers 
whereas in lower socioeconomic areas they are more likely to be bicycle or 








By nature, it is difficult to study in vivo human models of mTBI, and thus most 
information on the pathophysiology has traditionally come from animal 
models.  With advances in neuroimaging and software design, this is an 
emerging area of brain research. 
 
mTBI is not a single event or pathological process.  It is roughly divided up into 
two phases; the primary insult, which occurs at the point of impact causing 
immediate damage or deformation to the brain tissue, and the secondary 
disease process which occurs after the point of impact and can last minutes to 
months following the primary insult.  This secondary process involves 
metabolic, inflammatory and other changes at the cellular level.  The only way 
to prevent primary impact damage is to either prevent the injury itself or to 
minimize the impact, for example by the use of safety helmets.  The current 
focus in clinical treatment and research lies in trying to limit or prevent 

















It is also important to recognize the diversity of the mechanisms of injury 
within mTBI.  Falls, MVA’s, and assaults may all have similar clinical 
outcomes, but the mechanical forces that cause the injuries can be very 
different.  For example, the direct blunt force blow of a hammer or fist striking 
one part of the head is very different than the force of a global acceleration-
deceleration injury sustained in an MVA.  Yet patients with mTBI as a result of 
direct blunt force and global acceleration-deceleration will exhibit similar 
symptoms.  This may indicate distinct cellular pathophysiology pathways that 
ultimately culminate in similar clinical outcomes of mTBI.  With our current 
understanding, ultimately these culminate in similar clinical outcomes of mTBI 
and as such are treated similarly at present. 
 
Biomechanical models of mTBI suggest symptoms result from rotational force 
on the brain tissue of the cerebral hemispheres in the anterior-posterior plane 
around the brainstem, which is a fixed point and acts as a fulcrum (Figure 1.1) 
(24).  Focal brain injuries are more common after a linear 
acceleration/deceleration whereas diffuse injuries are more common after a 
rotational force injury.  It is more likely though that all injuries are a 








The mechanical event or injury leads to a secondary insult, which is a complex 
cascade of events leading to neuronal dysfunction.  The true nature of the 
cascade is difficult to determine with certainty due to the difficulty of collecting 
real time, in vivo data and the differences between human and animal models.  
There are several theories about mTBI pathophysiology that will be outlined 
below. 
 
One of the hallmarks of mTBI is ongoing neurological signs and symptoms 
after the initial biomechanical force, but an absence of macroscopic neural 
damage.  It therefore follows that microstructural changes result in the damage 
to cell or physiological function.  However, these microstructural changes-most 
likely multifactorial or from a series of interrelated events-have not been visible 
on traditional computed tomography (CT) or magnetic resonance imaging 
(MRI).  From the literature, microstructural damage can be divided into the 
following mechanisms: metabolic, vascular/loss of autoregulation, damage to 




Biochemical injury results in loss of the cell membrane integrity and disrupts 
cellular ion balance.  Specifically, resting state ionic balance is disrupted by the 
efflux of potassium and influx of sodium and calcium ions (Figure 1.2).  The 
elevated loss of intracellular potassium appears to be concomitant with 
glutamate release.  Cell membrane pumps requiring ATP are activated to try 
and reverse the ionic disturbance.  This process initiates cellular 
hyperglycolysis and a reduction in cell energy stores and subsequent 
accumulation of ADP.  This state of impaired metabolism can last 7-10 days 







Cellular calcium is transported into the mitochondria, however this can lead to  
reduced metabolism due to mitochondrial dysfunction and calcium overload.  
Mitochondrial calcium overloading is responsible for changes in inner 
membrane permeability with consequent malfunctioning, uncoupling of 
oxidative phosphorylation and organelle swelling.  These dysfunctional 
mitochondria become the source of reactive oxygen species (ROS) inducing a 
phenomenon known as oxidative stress.  Overproduction of ROS and an 
inability to clear them leads to irreversible cell change (26)(27).  Figure 1.3 










There is also research into the newly reported lymphatic pathway of the brain 
after mTBI, specifically with impairment of the ‘glymphatic’ pathway after TBI.  
This recently described pathway, which normally uses a brain wide 
paravascular pathway and cerebral spinal fluid (CSF) channels as a way for 
clearance of solutes becomes reduced by up to 60% in mice after TBI (29). This 
system may also be affected in humans post TBI.  
 
1.3.2 Vascular	changes	
The importance of adequate cerebral perfusion and oxygenation in the 
mechanism and the management of TBI is well documented.  The Brain 
Trauma Foundation Guidelines for the Management of Severe Traumatic Brain 
Injury evaluated the current evidence and made recommendations to prevent 
hypotension and hypoxia as a tool to limit secondary brain injury (30). 
 
Microvascular changes in the function of brain capillaries have also been 
described in the pathophysiology of TBI.  In rat models the consequences of 
these changes result in reduced cerebral blood flow and reduced oxygen 
delivery after the injury (31).  The initial metabolic changes and depletion of 
cellular energy stores are coupled with the normal or reduced cerebral blood 
flow in the initial stages post injury, which then exacerbates the metabolic 
changes (26).   
 
1.3.3 Blood	brain	barrier	
The blood brain barrier (BBB) is a physical interface between the brain 
parenchyma and the vascular system.  It is made up of near impermeable 
endothelial cell junctions that strictly regulate the flow of substrates into the 
brain.  It serves as the highest level of defense to protect the brain from 
systemic insults.  However, after brain injury this physical barrier can be 
mechanically disrupted and can become leaky (Figure 1.4).  This allows the 
influx of systemic inflammatory cells into the brain and hence potentiating an 











Cell damage from the primary injury triggers cellular inflammatory responses 
from glial cells to repair damaged tissue.  This process is called ‘reactive gliosis’ 
which aims to remove cellular debris and encourage tissue repair.  Reactive 
gliosis involves the activation of glial cells to release inflammatory mediators 
such as prostaglandins, free radicals, cytokines and chemokines.  These 
messengers in turn activate surrounding glia and neurons via autocrine and 
paracrine functions.  As well as acting on nearby neural cells, they also act 
systemically to recruit neutrophils, macrophages and lymphocytes from the 
peripheral immune system into the damaged brain tissue.  However excessive 
or sustained production of pro-inflammatory cytokines is deleterious in the 
recovery from TBI (32)(33).  
 
Inflammatory cytokines are secreted by the glia and neurons and either work in 
cell to cell communication or, when derived from glial cells, are mediators for 
cell growth and repair (Figure 1.5).  In both animal and human models 
examination has found high levels of Interleukin-1 (IL-1) in human CSF and 
brain parenchyma post TBI, and IL-1 has been shown to exacerbate neuronal 
injury in animal models.  Interlueikin-6, Interleukin-10 and Tumour necrosis 
factor-a (TNF a) are other important cytokines in TBI (32)(34), with similar 
deleterious effects.  
 
been reported in both head-injured patients and in animal
models of brain trauma.2 These activated cells release
mediators including prostaglandins, free radicals, com-
plement factors, and pro-inflammatory cytokines,10
which in turn induce the expression of chemokines and
cell adhesion molecules and mobilize immune and glial
cells to the injured site.11 Over time, subsequent produc-
tion of anti-inflammatory mediators suppresses both hu-
moral and cellular immune activation.
In addition to the infiltration of blood cells, the acti-
vation of resident microglia plays multiple roles within
the injured brain. The major task of microglia is the
removal of cell debris, which is required to attenuate
inflammatory processes and promote tissue remodeling.
In addition, howeve , activated microglia also release
various neurotoxic substances, such as reactive oxygen
and nitrogen species and glutamate, that may exacerbate
neuronal death.12 Although astrocyte reactivity, prolifer-
ation, and migration induced after brain trauma seems to
impair axonal regrowth, the presence of these cells
around th lesion provides a supporting milieu via the
release of neurotrophic factors promoting tissue repair
and neurogenesis.13
Over time, the sites o BBB leakage become sealed by
repair mechanisms; however, there is a period during
which the endothelium located in the region of damage
remains permeable to small molecules,14 thus sustaining
an altered homeostasis of the brain parenchyma and af-
fecting neuronal function. Studies from our laboratory on
a mouse model of focal TBI have recently demonstrated
that at 1 to 2 h after injury there is extensive diffusion of
intravenously injected horseradish peroxidase (a 40-kDa
glycoprotein) in the pericontusional tissue, which by 4 h
was no longer observed.15 At 4 days post-injury, how-
ever, markers of smaller molecular weight (!10 kDa)
continued to diffuse into the pericontusional cortex.
Thus, the complete restoration of the barrier seems to
require a time course that is much longer than that ob-
served for large molecules. This prolonged permeability
has the advantage of providing a window of opportunity
throug which drugs normally excluded from the CNS
can reach the injured brain tissue.
CYTOKINES AND CHEMOKINES PRODUCED
IN THE INJURED BRAIN
The inflammatory cascade activated after TBI is me-
diated by the release of pro- and anti-inflammatory cy-
tokines, which are polypeptides, normally barely detect-
able in healthy tissue but rapidly upregulated n response
to pathological or stressful challenges.11,16 Besides their
involvement in immune processes, cytokines also func-
FIG. 1. Blood–brain barrier (BBB) dysfunction following traumatic brain injury. The BBB is the physical interface between the brain
parenchyma and the vascular system. It consists of tightly placed endothelial cells, which regulate the passage of cells, molecules, and
ions into the brain tissue. Following brain injury, the integrity of the BBB is disrupted, resulting in the infiltration of red blood cells (RBCs)
and white blood cells into the parenchyma, thus allowing communication between the peripheral and resident immune cells; this
communication is edia ed by the release nd exchange of cytokines and other toxic or neurotrophic factors. Some of these mediators
can lead to the activation of glial cells, as well as neuronal cell death, whereas others promote regenerative mechanisms of the damaged
brain.
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Biomechanical forces directly act on neurons and damage their delicate 
microstructure resulting in loss of structural integrity.  Microtubule disruption 
due to axonal stretch can interfere with axonal transport and can result in 
axonal disconnection leading to axonal atrophy and shrinkage of the neuron, 
not always cell death as once thought (26).  This is termed Diffuse Axonal 
Injury (DAI) and is particularly evident after rapid acceleration/deceleration 
injury mechanisms (25).  There are some that regard mTBI as a mild form of 
DAI (27). 
 
There is still uncertainty across the literature as to the exact pathophysiology of 
mTBI and there are several potential pathophysiological mechanisms and 
theories as to the cause mTBI as detailed above.  Perhaps there are several 
concurrent mechanisms or a combination of many that cause mTBI.  Also 
worth considering is the possibility that different mechanisms of injury have 
different pathophysiologies.  The debate in this area continues and perhaps 





Like most areas of clinical medicine, information is gained by taking an 
accurate history from the patient but also from eyewitnesses.  Often the 
patients themselves have little or no recall of the events of the mechanism of 
trauma.  Hence there is great value in an eyewitness account of events.  In this 
way, the diagnosis of mTBI is based on the history of the event and clinical 
examination, which itself is normal in most cases as most mTBI patients have 
often returned to GCS 15/15 (a normal score) by the time they present for 
medical attention.  More subtle symptoms and signs may include the pale, 
diaphoretic, nauseated or ataxic patient (35).  Visual disturbance such as 
diplopia or photosensitivity are also common (36). 
 
No robust or reliable radiological or biochemical markers have been developed 
to diagnose mTBI (3)(37).  Candidate biomarkers including glial fibrillary acidic 
protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) have shown 
some use in animal and early human studies, but are not yet reliable enough 
for clinical use (3)(38).  Traditional neuroimaging techniques such as Computed 
Tomography (CT) and magnetic resonance imaging (MRI) are in most cases 
reported as normal.  However, some new MRI techniques show promise and 
these will be discussed in the MRI section of this thesis (Section 3).  
 
1.5 Traditional	Neuroimaging	
Computed Tomography of the head is the front-line investigation tool in most 
Emergency Departments (ED).  With the large number of people presenting to 
hospital ED following mTBI, there remains a lot of uncertainty as to who to 
image.  The decision to image must balance the financial cost and potential 
harm from radiation exposure, especially with children, against the risk of not 
missing a surgically significant pathology such as an extradural haematoma.  
Many guidelines have been proposed for patient selection to produce the 
highest yield of significant pathology.  The most commonplace method used in 
hospital ED is the Canadian CT Rule (39).  This is based on evidence gained by 
a prospective cohort study of ten large ED in Canada, totaling 3121 patients 
with GCS 13-15 after mTBI.  The main outcome measures were the need for 
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neurosurgical intervention and clinically significant brain injury on CT.  It 
identified high and medium risk factors as predictors for clinically significant 
brain injury.  Predictors are summarized in Figure 1.6. 
 
 
The high-risk factors were 100% sensitive (95% CI 92-100%) in identifying the 
patients requiring neurosurgical intervention.  These criteria would mean 32% 
of the mTBI population would undergo CT scanning.  Further analysis with all 
seven factors (both high and medium risk) showed 98.4% sensitivity (95% CI 
96-99%) and 49.6% specificity (95% CI 48-51%). 
 
It is important to note that alcohol was not an identified factor in this tool and 
patients on anticoagulation were also excluded from the study.  There must be 
a lower threshold of clinical concern for these two factors as alcohol can mask 
neurological signs and anticoagulation may potentiate any intracerebral 
bleeding events.  These should be judged on a case by case basis with clinical 
correlation required.  The Canadian CT rule is also not for use in children 
under the age of 16 years; there are separate clinical guidelines for children.  In 
New Zealand we favour the use of the Starship Children’s Health (SSH) 



























MRI is another noninvasive tool for imaging the brain after mTBI.  The use of 
MRI is not routine in day to day practice, but is useful in cases where the CT 
scan is normal but the patient has significant or unexplained symptoms.  New 
MRI techniques such as diffusion-weighted, susceptibility-weighted and 
functional imaging, as well as MR spectroscopy, are starting to be reported in 
the mTBI literature.  Another imaging technique, positron emission 
tomography, is also an emerging area of research (41)(42). 
 
Regardless of neuroimaging tool used, the most common mTBI outcome is an 
absence of positive clinical findings and for scans to be reported as normal.  
Abnormal imaging results such as traumatic subarachnoid blood, small 
intraparenchymal contusion or even skull fractures do not preclude a diagnosis 
of mTBI, as the diagnosis is based on clinical history and physical examination 
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rather than imaging results.  A negative scan does not give any prognostic 
benefit; patients with normal scans can still have significant mTBI symptoms 
and develop chronic sequelae. 
 
1.6 Management	
The majority of mTBI cases do not require admission to hospital.  They can be 
managed in a patient’s home environment with supportive and expectant 
management.  Symptoms can be characterized as somatic, emotional or 
neurocognitive; common symptoms of mTBI are tabulated in Table 1.3.  Many 
of these symptoms are extremely common.  For example, it is estimated that 
the incidence of headache alone is as high as 90% at one month and 25% at 1 
year post-injury (24).  
 
Table	1-3		Symptoms	of	mTBI	
Somatic Emotional Neurocognitive 
Headache Feeling frustrated Poor 
attention/concentration 
Balance disturbance Anxiety Slowed response 
Dizziness Depression Poor memory 
Restlessness Irritability Slowed thinking 
Nausea/vomiting Emotionally labile  
Visual change e.g. 
diplopia 
Fatigue/low energy  
Insomnia/Sleeping more   
Noise sensitivity   
Photophobia   
Tinnitus   
Made	with	data	from	(8)	(21)	(36) 
The initial recovery phase is that of complete rest in a low stimulus 
environment.  This phase should last until all the symptoms have resolved and 
this duration varies person to person.  Once symptoms have completely 
resolved, gradual return to work, school or sport is recommended.  Exposure to 
normal stimuli is introduced in a stepwise manner (21)(43). 
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Pharmacotherapy is also frequently administered, in the form of simple 
analgesia and antiemetics with care to avoid opiates, if possible.  For those with 
dizziness, the use of promethazine and vestibular therapy have been shown to 
be effective treatments (24). 
 
Upon diagnosis, information about what to expect and how to manage 
symptoms is given to the patient and their family (44)(45)(46)(47).  The 
recovery period for mTBI is followed by the rehabilitation phase.  There is no 
single plan or course of rehabilitation for everyone, rather rehabilitation is 
individualized to the patient (5).  Follow up and further management is with 
the patient’s General Practitioner (GP) and the ACC Concussion Clinic.  The 
Concussion Clinic provides early intervention rehabilitation and is made up of 
interdisciplinary services providing assessments and therapies tailored to the 
individual’s recovery needs (48). 
 
1.7 Prognosis	
Most patients that suffer mTBI make a complete recovery by 3 to 12 months 
following the injury (49).  However a proportion of patients will have ongoing 
symptoms; this is known as Post-Concussion Syndrome (PCS)(36).  It is 
estimated that patients with PCS make up approximately 15% of all mTBI 
patients at 1 year after their initial injury (35).  PCS will be discussed further in 
section 1.8. 
 
The young and old suffer disproportionately from mTBI.  Those less than 20 
years-of-age have been found to have a longer recovery and are more likely to 
experience persistent symptoms than older adults (2)(36).  This could be for 
several reasons, including less skull thickness, incomplete myelination and 
greater head to body ratio in younger individuals.  Within the brain 
parenchyma, perhaps the immature brain is more vulnerable to biochemical 
damage (36).  The very old are also at higher risk of developing PCS after TBI, 
with a tenfold increase in risk of adverse outcome compared to the age group 
15-25 years (2).  Those experiencing a mTBI over the age of 65 are more likely to 
develop chronic sequelae and have lower functional independence (36)(49).  It 
has been suggested that this could be due to the age related changes in the 
brain such as reduced brain volume (50). 
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Repetitive head trauma can result in progressive tauopathy known as Chronic 
Trauma Encephalopathy (CTE).  CTE results in symptoms of memory loss, 
difficulties with higher executive function, mood and behavior changes, as well 
as movement and coordination disorders (10)(51).  Recent public interest in 
CTE may give the appearance of this being a relatively new disease entity, but 
it was described in boxers in the early to mid-1900s (52)(53).  Whereas the 
symptoms of mTBI, and even PCS, are temporary and directly attributable to 
the injury, CTE is a chronic neurodegenerative condition that manifests often 
decades after the initial insult.  At this stage, it is thought to be related to 
multiple events of mTBI, and even sub-concussive events, not just one episode 
(9).  As with mTBI the pathophysiology of the condition is also not very well 
understood.  It has been suggested that it is a combination of axonal stretching 
and subsequent neurodegenerative changes (9).  There are many varied post 
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While the incidence is thought to be rare, the only real indication is from a post 
mortem study of retired professional American Football players.  Based on 
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player deaths and those who had a post mortem performed, prevalence is 
estimated at 3.7% (10).  However, it is difficult to generalize these findings as 
only athletes with signs of the disease had post mortems performed and this is 
also not a representative sample of the mTBI population. 
 
1.8 Post	Concussion	Syndrome	
PCS frequency and natural history are not certain, but it is estimated that PCS 
affects approximately 15% of all mTBIs one year after their initial injury 
(35)(54).   
 
The International Classification of Disease(ICD)-10th revision (1992) defines 
criteria for diagnosis of PCS as (8)(24): 
A.  History of head trauma with loss of consciousness preceding symptoms 
onset by a maximum of 4 weeks. 
B. Symptoms in 3 or more of the following: 
a. Headache, dizziness, malaise fatigue, noise tolerance 
b. Irritability, depression, anxiety, emotional lability 
c. Subjective concentration, memory, or intellectual difficulties 
without neuropsychological evidence of marked impairment. 
d. Insomnia 
e. Reduced alcohol tolerance 
f. Preoccupation with above symptoms and fear of brain damage 
with hypochondriacal concern and adoption of sick role 
 
Another definition was presented in the Diagnostic and Statistic Manual for 
Mental Disorders- IV edition in 2000 (DSM-IV).  The DSM-IV criteria for PCS 
are; 
 
A. “A history of head trauma that has caused significant 
cerebral concussion.  Note: the manifestations of concussion 
include the loss of consciousness, PTA, and less commonly 
posttraumatic onset of seizures.  The specific method of 
defining this criterion needs to be established by further 
research. 
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B. Evidence from neuropsychological testing of quantified 
cognitive assessment of difficulty in attention 
(concentrating, sifting focus of attention, performing 
simultaneous cognitive tasks) or memory (learning or recall 
information). 
C. Three (or more) of the following occur shortly after the 
trauma and last at least three months: 
i. Becoming fatigued easily 
ii. Disordered sleep 
iii. Headache 
iv. Vertigo or dizziness 
v. Irritability or aggression on little or no provocation 
vi. Anxiety, depression, or affective instability 
vii. Changes in personality (e.g. social or sexual 
inappropriateness) 
viii. Apathy or lack of spontaneity 
D. The symptoms in criteria B and C have their onset 
following head trauma or else represent a substantial 
worsening of preexisting symptoms. 
E. The disturbance causes significant impairment in social or 
occupational functioning and represents a significant 
decline from a previous level of functioning.  In school age 
children, the impairment may be manifested by a 
significant worsening in school or academic performance 
dating from the trauma. 
F. The symptoms do not meet criteria for Dementia Due to 
Head Trauma and are not better accounted for by another 
mental disorder (e.g. Amnesic Disorder Due to Head 
Trauma, Personality Change due to Head Trauma).” 
 
While similar these two definitions have some striking differences.  The most 
obvious is that the DSM IV requires symptoms to persist for at least 3 months, 
as well as having more criteria needed for diagnosis.  There have also been 
studies comparing the difference between the diagnostic accuracy of both 
definitions.  Boake et al. (55) performed the first prospective study comparing 
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the prevalence and specificity of diagnosing PCS by comparing 178 TBI 
patients with 104 patients with only extracranial injuries.  They found 
prevalence of PCS was higher using the ICD-10 definitions- 64% ICD-10 vs 11% 
DSM IV.  However, neither definition was specific to TBI as over one third of 
subjects in the extracranial group also met criteria for PCS diagnosis. 
 
The DSM IV has now been replaced by the DSM V (56) and PCS has been 
removed and replaced within a category of Mild or Major Neurocognitive 
Disorders due to Traumatic Brian Injury.  It is more focused on cognitive and 
neuropsychiatric consequences of TBI and the effect on everyday life (57).   
 
There appears to be a variety of interacting factors, both biological and 
psychological, underlying PCS.  There has been considerable debate in the 
literature as to the origin of PCS symptoms, with many suspecting a 
psychological rather than biological origin (47)(54)(58)(59)(60).  One of the 
arguments for the psychological basis is that the symptoms of PCS are not 
specific to this disorder.  Rather they can be seen in many other conditions such 
as chronic pain (CP), baseline psychological conditions such as depression or 
post-traumatic stress disorder (PTSD) and even to varying degrees amongst the 
healthy population (8)(43)(61)(62)(63).  CP will be discussed in the following 
chapter (Chapter 2). 
 
mTBI represents a collection of symptoms that are both wide and variable in 
frequency and severity.  Baseline inter-individual differences or pre injury 
factors may also influence outcomes and development of PCS (36).  Pre injury 
baseline characteristics including young or older age, female gender, lower 
educational background, poor socioeconomic status, positive psychiatric 
history or emotional personality traits and alcohol and drug use have been 
identified as factors that can increase the severity of or yield poorer recovery 
from mTBI (36)(54)(62)(58).  For example, those who used oral analgesics pre 
injury were more likely to develop PCS; this has been suggested to be evidence 
for poor coping style (64). 
 
While mTBI itself is more common in males, the development of post mTBI 
symptoms are said to be higher in females (2)(36)(65).  Bazarian et al. (64) 
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investigated the independent association of sex with outcome after mTBI.  
Using a study population of 1126 mTBI patients, males were found to have 
lower odds of having symptoms post mTBI at 3 months than females (OR 0.62, 
95% CI: 0.50, 0.78; p<0.0001).  However, it is uncertain whether this is a true 
finding or if it merely represents reporting bias in that females are more likely 
to report symptoms than males.  The human results contrast with experimental 
animal evidence, with female rats having been shown to have a better cognitive 
performance compared to male rats following mTBI (66).  It was postulated 
that progesterone and its metabolites are neuroprotective.  However, in 
humans, even when accounting for confounding factors, females have higher 
rates of post mTBI symptoms (58). 
 
1.9 Diagnosis	
There are currently no reliable biochemical or radiological markers for the 
diagnosis of PCS.  As such it is purely a clinical diagnosis based on the clinical 
criteria outlined above. 
 
1.10 	Management	
There are several studies which suggest education and the delivery of 
knowledge and information to a patient about mTBI and PCS helps improve 
recovery time (3)(43)(54).  For example, a face to face consultation and an 
information sheet with an explanation of mTBI symptoms, including what to 
expect, how to manage these symptoms, and reassurance that the natural 
history of mTBI is that symptoms will improve over time, has been shown to 
improve outcomes (58)(67).  This knowledge gives patients reassurance and 
power to monitor their condition. 
 
Patients with long term PCS ideally require management by an 
interdisciplinary approach, such as that provided through ACC Concussion 
Clinics.  In these settings, neurocognitive testing and cognitive rehabilitation 
may be employed.  Cognitive Behavioral Therapy (CBT) has been useful in the 
treatment of mood and anxiety symptoms (43).  Pharmacological treatments 
include a trial of Selective Serotonin Reuptake Inhibitors (SSRI) for depressive 




PCS natural history is not well understood.  This is possibly due to symptom 
overlap with numerous mental health conditions and the lack of long term 
follow up data.  However, a prospective long-term study by Zumstein et al. (68) 
followed 86 mTBI patients, 46 % of the initial study group of 176 patients, 10 
years after the initial mTBI.  Thirty-seven percent of those patients followed 
showed a decline in general health and quality of life. 
 
PCS is a significant and debilitating condition for those affected.  While some 
strategies and treatments are available there remains much to learn of the 





Pain is a normal response to acute injury, but in a small group of patients, pain 
persists beyond the usual period of healing, and is termed “chronic pain” (CP).  
Chronic pain has many similarities to mTBI and especially PCS.  For example, 
as with mTBI there are many definitions of CP and these variations make 
comparisons across studies difficult.  The pathophysiology for the 
development of CP is also not well understood; just like PCS.  Questions 
abound as to why some mTBI patients go onto develop PCS, and why only 
some acute pain sufferers go onto develop CP?  Chronic pain and PCS share 
clinical features, especially with respect to the time course and psychological 
factors involved in the development of each condition.  Given these similarities, 
I have used a group with chronic pain to compare with mTBI patients, in 
addition to a healthy control group.  The rationale for this comparison was to 
evaluate the PCS and CP groups to look for MRI similarities and this will be 
further discussed in section 2.6.  This chapter will discuss in more detail 
chronic pain and its relationship to mTBI.  
	
2.2 Definition	of	Chronic	Pain	
Definitions of CP vary.  One of the most comprehensive comes from the 
International Association for the Study of Pain (IASP) which defines CP as: 
“pain without biological value that has persisted beyond the normal tissue 
healing time (usually taken to be three months)” (69).  This definition goes 
further to define the origin of different types of chronic pain including (70):  
• Chronic Primary pain: a pain in one or more anatomical regions, which 
is multifactorial in contribution and causes significant emotional 
distress. 
• Chronic Cancer pain: pain caused by cancer itself or its treatment. 
• Chronic Post-Surgical and Post-Traumatic pain: pain developing after a 
surgical procedure or tissue injury from any trauma and persisting 
beyond the healing process of 3 months. 
• Chronic Neuropathic pain: pain caused by a lesion or disease of the 
somatosensory nervous system including skin, musculoskeletal and 
	 24	
visceral organs and may involve the peripheral or central nervous 
system. 
• Chronic Headache and Chronic Orofacial pain: headache or orofacial 
pain on at least 50% of days during 3 months. 
• Chronic Visceral pain: pain that is persistent or recurring from internal 
organs. 
• Chronic Musculoskeletal pain: pain arising from bones, joints, muscles, 
the spine or other related soft tissue. 
 
The current International Classification of Disease (ICD-10) includes chronic 
pain but doesn’t reflect the epidemiology.  The IASP is working in 
collaboration with the WHO on the upcoming ICD-11 definitions to extend the 
pain categories similar to those listed above.  The ICD-11 is expected to be 
released in 2018 (71). 
 
The New Zealand Pain Society supports the IASP definition(72).  This 
definition is used at the Pain Management Service, from where the participants 
of this study have been recruited from. 
	
2.3 Incidence	
As with mTBI, Definitions of CP vary.  One of the most comprehensive comes 
from the International Association for the Study of Pain (IASP) which defines 
CP as: “pain without biological value that has persisted beyond the normal 
tissue healing time (usually taken to be three months)”(69).  Definitions of CP 
vary.  One of the most comprehensive comes from the International 
Association for the Study of Pain (IASP) which defines CP as: “pain without 
biological value that has persisted beyond the normal tissue healing time 
(usually taken to be three months)”(69).  In 1999, a UK population-based study 
analysed a random postal questionnaire of 3605 people (73).  It found 46.5% 
equivalent of the population self-reported chronic pain symptoms.  This figure 
is significantly higher than that quoted in the literature and illustrates the 
variation in incidence.  A similar screening population-based screening study 
in Europe (2006) surveyed 46,394 participants in different countries and 
reported a mean prevalence rate of chronic pain of 19%, with a range of 12-30% 
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between countries (74).  These studies illustrate the wide variability in reported 
prevalence.  This variation may well reflect the different definitions of chronic 
pain as well as the body of patients of patients who ‘suffer in silence’ and may 
not seek medical attention.  New Zealand specific data from the New Zealand 
Pain Society estimates one in six New Zealanders suffer with chronic pain (72). 
 
2.4 Pathophysiology	
The majority of patients with acute pain will fully recover with less than 5% 
transitioning into chronic pain (75).  The mechanisms that drive the 
progression to chronic pain are not well understood.  Several hypotheses have 
been put forward, including social, psychological, neural or genetic factors, but 
no firm causation has been established. 
 
Once peripheral pain has been elicited, it is mediated and modulated by spinal 
and supraspinal mechanisms.  Some suggest that neuroplasticity of the central 
nervous system facilitates transition from acute to chronic pain (76)(77).  One 
potential pathway implicates astrocytes.  Astrocytes within the central nervous 
system play an important role in releasing neurotransmitters and other cellular 
signaling mechanisms involved at the cellular level in generating chronic pain 
(78).  Upregulation or over expression of neurotransmitters can cause 
exaggerated pain states.  Astrocytes release neurotransmitters, such as the 
excitatory amino acid glutamate, which in excess increases neuronal 
excitability in chronic neuropathic pain (79).  Astrocytes have also been shown 
to secrete 1b, a pro-inflammatory cytokine, and nerve growth factor (NGF) 
which are both involved in the cellular level in the generation of chronic pain 
(78).  These detailed cellular mechanisms involved in the generation of chronic 
pain are not discussed further as they are beyond the scope of this thesis. 
	
Baseline psychosocial characteristics of patients are also predictive of transition 
to chronic pain.  Linton performed a systematic review of thirty-seven studies 
to summarize the psychological variables in the development of neck and back 
pain and concluded: “Psychosocial variables are clearly linked to the transition 
from acute to chronic pain disability.” (Level A evidence) (80).  The strongest 
psychosocial predictor is a history of depression or low mood.  Meyer et al. 
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examined chronic pain and depression using a Health Outcome Survey of 
55,690 subjects 2 years after initial survey and identified a “dose-response” 
relationship between CP and depression (81).  That is, low levels of depression 
were associated with low levels of chronic pain and high levels of depression 
were associated with high chronic pain.  Other predictive psychosocial factors 
include patient attitude to pain, somatization, health seeking behavior as well 
as the strength and duration of the acute pain episode (80)(82)(83)(84)(85). 
	
2.5 Brain	changes	in	Chronic	Pain	
In recent times, there has been much research with MRI into the brain structure 
and function of patients with chronic pain.  Little is known about the 
pathophysiology of chronic pain and neuroimaging is being used to explore the 
possible underlying changes or mechanisms.  There is debate as to whether the 
structural brain changes found on MRI are the cause or the result of the chronic 
pain.  The current evidence suggests these morphological brain changes are the 
latter, due to neuroplasticity resulting from a noxious stimuli such as chronic 
pain.  Interestingly there have been studies to show that after removal of the 
chronic stimulus, for example an osteoarthritic hip joint replaced with a total 
hip joint replacement, as symptoms improve the morphological brain changes 
also improve and almost return to pre morbid normal limits (76)(86)(87). 
 
Several studies which provide evidence to show structural brain changes in 
patients with CP, in particular a reduction of grey matter volume.  One 
examined the brain morphology of 10 patients with fibromyalgia compared to 
10 healthy subjects.  The authors showed significantly less total brain and grey 
matter volume and a 3.3 times greater age-associated decrease in grey matter 
compared to controls (88).  However, these grey matter changes are not 
necessarily permanent.  For example in a pilot study published in 2009 by 
Rodriguez-Raecke et al. (86), 10 patients with osteoarthritis of the hip were 
followed pre and post hip replacement with structural MRI brain scans.  At 
baseline pre-operatively when compared to normal controls, the patients with 
chronic hip pain had reduced grey matter in the anterior cingulate cortex, right 
insula cortex, and operculum, dorsolateral prefrontal cortex, amygdala, 
brainstem and cerebellum.  Interestingly they also found that when the same 
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participants were scanned a second time when pain free post operatively, the 
resolved pain patients showed increased grey matter volume, in particular in 
the dorsolateral prefrontal cortex, anterior cingulate cortex, amygdala and 
brainstem.  They suggest that, rather than be caused by brain damage, the 
morphological changes as a result of the noxious stimuli are reversible so that 
when the causative stimulus is removed the morphological changes improve 
(87).  Rodriguez-Raecke et al. repeated the study in 2013, this time with 20 
patients and monitored structural changes up to a year post hip replacement.  
They found the same changes, with increased grey matter in the previously 
listed areas but also in the premotor cortex and the supplementary motor area 
(87). 
 
All eight studies using volumetric analysis to investigate the structure of the 
brain in chronic pain showed a reduction in grey matter volume in chronic pain 
compared to age/sex matched normal controls.  Regardless of the location of 
the pain or pain syndrome mechanism, the most common findings were of 
reduced grey matter volume in cingulate gyrus, orbitofrontal cortex, the insula 
and the dorsal pons.  The reasons for this loss of grey matter volume are 
unknown but have been thought to be due to cell atrophy, reduced cell size, or 
a loss of the synaptic architecture (76). 
 
Functional MRI (fMRI), Positron Emission Tomography (PET), 
Electroencephalogram (EEG) and Magnetoencephalography (MEG) studies 
have also been used to further illustrate that the areas of the brain involved 
with acute pain to various stimuli are the primary and secondary 
somatosensory, insula, anterior cingulate, prefrontal cortices and the thalamus.  
These supratentorial anatomical areas are involved in the processing and 
modulation of pain.  The brainstem, particularly the periaqueductal grey 
matter and the brainstem reticular formation play a role in the descending 
regulation of pain (89)(90)(91).  In normal subjects the acute pain perception 
pathways were ‘partially’ different from those of participants with chronic pain 
(92).  The review identified that the regions of the brain engaged with chronic 
pain were the cognitive/emotional regions namely the prefrontal cortex via the 
spinobrachial, spinothalamic and spinoreticular pathways.  It is suggested that 
chronic pain is less about sensory processing and more likely about increased 
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emotional and cognitive processing (92).  This has also been shown in chronic 
Complex Regional Pain Syndrome (CRYPS) (93).  Early work such as the Gate 
Control Theory of pain, proposed by Melzack and Wall in 1965, theorised that 
the interrelated parts of the brain were responsible for the perceptions of pain-
thalamus, limbic system, hypothalamus, reticular formation, parietal and the 
frontal cortex-but also surmised that the emotive responses played a role in the 
pain response (94). 
 
A longitudinal observational study by Vachon-Presseau et al., used anatomical 
and diffusion tensor imaging (DTI) MRI to follow acute back pain over 3 years 
to either recovery or chronic pain, also with a normal control group for 
comparison.  The authors found that a higher incidence of connections within 
the dorsal medial prefrontal cortex-amygdala-nucleus accumbens was 
predictive of chronic pain at 1 year post onset of pain (95).  This finding 
suggests that CP is a maladaptive response with addictive corticolimbic 
properties responsible for its development.  They also found smaller 
morphometric measures of the amygdala and hippocampal in patients with 
chronic pain (95). 
	
2.6 Chronic	Pain	and	mTBI	
As detailed in chapter 1 the symptoms of Post-Concussion Syndrome (PCS) are 
not particular to mTBI and have cross over into a variety of conditions 
including chronic pain.   
 
The underlying time course of each condition is similar; both mTBI and the 
majority of CP patients start with an initialing event-an injury or stimulus.  
Only a small percentage in each of the mTBI or acute pain groups go onto 
develop chronic symptoms.  Significantly, there are psychosocial factors 
associated with this progression and baseline pre-morbid psychological 
conditions and personality traits that will impact the development of both 
conditions.  Symptoms of PCS are similar to those with CP.  Studies with direct 
comparison between PCS and CP show similar impairment across physical, 
cognitive and somatic domains (61)(63)(96). 
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Not surprisingly, given the current theory of similar underlying psychological 
factors in the development of both CP and PCS, there have also been similar 
psychological and cognitive therapies used for the treatment of both 
conditions.  For example, CBT is used for the treatment of cognitive symptoms 
in both conditions (43)(97). 
	
Can one take the comparison between PCS and CP a step further and ask if 
there are common mechanisms contributing to the chronicity of each 
condition?  Furthermore, MRI has already been used to investigate the brain 
changes associated with chronic pain.  Perhaps comparison with MRI changes 
in PCS might aid understanding of the pathophysiology of both conditions.  
Thus, I postulate that CP patients comprise a suitable active control group in 







Magnetic resonance imaging (MRI) is a non-invasive imaging technique that 
uses magnetic fields and radiofrequency waves to create detailed images of the 
body.  Specifically, MRI utilizes the electromagnetic properties of hydrogen 
protons, found in the form of water making up 60% of body weight, to form an 
image.  Unlike x-ray or CT, MRI uses no ionizing radiation.  The higher 
magnetic field results in stronger Magnetic Resonance (MR) signals (98).  In 
clinical practice 1.5T magnets are common in hospitals, but now 3T scanners 
are becoming more widely used.  Today, an MRI scanner is found in almost 
every major hospital in the western world and is a vital diagnostic tool to 
physicians.  This chapter will outline basic MR Physics and the role of MRI in 
TBI with further discussion of the physics in the MR techniques used in this 
study. 
3.2 Basic	MR	Physics	
Each hydrogen nucleus contains a positively charged proton, which possesses a 
constant intrinsic nuclear spin around its own axis.  This produces a small 
magnetic moment, which means that in the presence of an external magnetic 
field, protons will tend to align with the magnetic moment and begin to 























There is a weak tendency for protons to align with the external magnetic field 
(longitudinal, or B0 direction) forming the net magnetization vector (NMV).  
When a radiofrequency plus (RF) is applied at the resonant frequency (the 
frequency of the precessing protons, also called the Lamor frequency), the 
NMV is moved out of the B0 plane (Figure 3.2).  The NMV is rotated away 
from the direction of the large external magnetic field (B0); the resulting change 
in direction is called the flip angle.  The flip angle itself depends on both the 
duration and amplitude of the RF pulse.  The frequency required to cause this 
rotation away from the B0 direction is called the Lamor frequency.  The Lamor 
frequency is given by the Lamor equation (98)(101)(99):  
 
 
w= Lamor frequency in megahertz 
B= the strength of the magnetic field in T 
g= the gyromagnetic ratio (a constant value specific to each type of nucleus, for 
hydrogen 42.5 MHz/T) 
 
The Lamor equation is the cornerstone of MRI physics as it describes the 











Once the NMV is rotated away from the longitudinal plane into the transverse 
plane, the signal fades back to its equilibrium state via two processes.  The first 
is called T1 relaxation or ‘spin-lattice interaction’.  This is where excited 
protons lose excess energy to the surrounding environment (or lattice) and 
return to their original equilibrium orientation.  The T1 time of a tissue is 
defined as the time it takes for 63% of the equilibrium longitudinal 





















or spin-spin relaxation.  This occurs as energy is transferred between adjacent 
spins (protons).		The T2 time is defined as the time it takes for the transverse 
magnetization to drop to 37% of its original size (Figure 3.3).  Of note, for any 
tissue T2 is always shorter than T1.  Different tissues take different amounts of 
time to return to equilibrium, hence they have different T1 and T2 times.  For 
example, fluids have longer T1 and T2 times compared to more solid tissues 
that contain higher amounts of lipids or proteins, which have shorter T1 and 
T2.  These differences give rise to a cornerstone of MR imaging and by tuning 
various imaging parameters one can exploit differences in T1 and T2 values to 












After excitation, the precessing NMV is tipped into the transverse plane.  This 
rotating magnetization, in accordance with Faraday’s law of induction, induces 
a current within the receiver coil and provides the raw signal for the MR signal.  
This detected signal is then reconstructed to form the image (104)(98)(101)(6). 
 
The digital image is three dimensional and made up of voxels (a 3D pixel).  
Each voxel is assigned a value that corresponds to a signal intensity.  A voxel is 
a cube usually measuring 1-2mm on a side and the higher the resolution of the 















With the lack of traditional radiological evidence of brain injury combined with 
the advent of advanced MRI technologies, there has been increasing MR 
evidence of the structural, functional and metabolic imaging changes in 
patients with mTBI.  The most robust findings have come from Diffusion 
Tensor Imaging (DTI), with findings in regional and whole brain degradation 
both in acute stages of injury with the detection of haemosiderin staining and 







With reference to advanced MRI techniques and their use in TBI the White 
Paper from the Journal of the American College of Radiology 2015 states “there 
is insufficient evidence supporting the routine clinical use of advanced 
neuroimaging for diagnosis and/or prognostication at the individual patient 
level (class IIb recommendation)” (42).  At present these advanced MRI 
techniques are still being assessed for validity and effectiveness before use in 






















Structural MRI is a static image of the brain, providing high resolution, 
anatomical information.  A number of MRI sequences can be used, however, in 
this thesis, I used T1-weighted images to investigate atrophy (106).  Extensive 
preprocessing of the structural data facilitates segmentation into grey, white 
and CSF maps, allowing investigation of volumes (106).  Thickness of the 
cortex can also be calculated. Common brain segmentation packages include 




The cerebral cortex is comprised of layers of folded neurons.  The thickness of 
the cortex has been used in the study of neurodegenerative conditions and 
emerging research in mTBI.  However, the thickness of the brain cortex is not 
uniform due to different arrangement of cell architecture.  For example, 
Brodmann’s area 3 (primary sensory area) on the posterior aspect of the central 
sulcus is only 2mm in average thickness, as it contains tightly packed granule 
cells, whereas Brodmann’s area 4 (primary motor area) on the anterior aspect of 
the central sulcus, is often more than 4mm in thickness as it contains giant 
pyramidal cells of Betz.  Regional variations and the highly sensitive nature of 
brain anatomy make it a difficult task to manually trace.  It takes several days 
to manually trace the entire brain and even then, this may measure volume 
rather than thickness.  This is because to measure thickness the location and 
orientation of the grey/white matter and the pial surfaces must be precisely 
known (111)(112).  New computer modelling software has become available to 
calculate cortical thickness.  Over the years this software has been refined as 
initial programs struggled with accuracy due to the close proximity of the deep 
sulci not being penetrated by the models causing partial volume effects (112).  
Freesurfer is a software developed out of Harvard (111), specifically designed 
to calculate cortical thickness across the entire brain.  This is one approach I 
will use in this thesis. 
 
3.3.2 Diffusion	Tensor	Imaging	(DTI)	
DTI has been used to investigate microstructural white matter change after 
mTBI (105)(42)(113).  Diffusion MR techniques were first described by Stejskal 
and Tanner in 1965 when they outlined a diffusion pulse sequence, which still 
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forms the basis of modern DTI (114).  However, it wasn’t until the 1980s that 
the technology was routinely available on clinical MRI machines (115).  The 
first published literature of the use of DTI and mTBI was in 2002 by Arfanakis 
et al. (116) and since then there has been a large amount of research performed.  
An advanced PubMed search with the terms ‘mild traumatic brain injury’ AND 
‘diffusion tensor imaging’ yielded 247 results in the last five years alone. 
 
Diffusion is a primary biological process that describes the microscopic 
movement of molecules due to thermal motion.  This process is also referred to 
as Brownian motion, and forms the basis of DTI.  Diffusion follows a Gaussian 
process, where molecules move randomly over a distance and can be described 
by the diffusion coefficient (D).  D is dependent on size of the molecules, 
temperature and the viscosity of the medium (117)(118)(119)(120).  
 
Diffusion is affected by the inherent properties of the surroundings in which 
this process occurs.  Isotropic diffusion is the process by where molecules 
travel equally in all directions.  In the brain, isotropic diffusion occurs in the 
CSF of the ventricular system as there is little restriction of movement (Figure 
3.5, left panel).  In other tissues, such as highly ordered and organized white 
matter, the diffusion of water molecules is direction dependent, known as 
anisotropy diffusion (Figure 3.5, right panel).  In the white matter of the brain, 
water molecules diffuse more easily parallel to the long axis of the axons rather 
than perpendicular to the tract, so in white matter the direction of water 
movement is the direction of the fiber bundle.  Also in different body tissues 
water molecules interact with cell membranes which impede its movement.  
The movement of water between the intra and extracellular spaces, within the 
extracellular space itself, and tissue cellularity can also affect diffusion.  The net 
movement of molecules across an area of tissue per second is called the 
Apparent Diffusion Coefficient (ADC), and is reported as cm2/s or mm2/s.  
Where there is free (unrestricted) diffusion, the ADC value is high, whereas 














In diffusion imaging an external parameter called the b value reflects the 
strength, duration and spacing of the pulsed gradients used to generate the 
diffusion weighted images.  The larger the b value, the more diffusion 
weighting in the final image, however this comes with increased signal noise 
and possibly more mechanical vibration artefacts.  The b value range can vary 
substantially depending on acquisition, but most published literature uses a 
standard b value of 1000s/mm2.  The b value is defined by the Stejskal and 
Tanner equation which uses the excitation pulse given between a pair of 
gradient pulses (Figure 3.6) (101)(113)(114)(121)(122). 
 
Stejskal and Tanner equation; 
b = 𝛾"𝐺"𝛿"(Δ − 𝛿/3) 
g= gyromagnetic ratio 
G= amplitude 
d= duration 
D= time interval of the diffusion gradient 
 



























The tensor is the most common way to describe the multi-directional properties 
of diffusion.  The diffusion tensor is represented as a 3x3 matrix which 
represents the movement of water in 3-D (Dxx, Dxy, Dxy, Dyx, Dyy, Dyz, Dzx, 
Dzy, Dzz), with x,y and z being x-axis, y-axis and z-axis.  To determine the 
tensor, diffusion must be measured in at least six different directions.  An 
additional non-diffusion weighted image is also needed as a reference 
(99)(118)(121)(122). 
 
The diffusion tensor can be represented by an ellipsoid (Figure 3.7).  The long 
axis represents the direction of greatest diffusion, called axial diffusivity (l1, 
principle eigenvalue and its direction is the corresponding eigenvector).  The 
minor axes are used to describe radial diffusivity ((l2 +l3)/2).  Using the axes, it 
is possible to calculate other values that can provide information about axonal 











Fractional anisotropy (FA) is a scalar measure that quantifies degree of angular 
variation of the diffusion of water.  Values vary between 0 and 1; where 0 
represents isotropic diffusion, i.e. a perfect sphere, and 1 represents diffusion in 
a single direction only, where the diffusion ellipsoid is a thin cigar-like shape.  
Therefore, areas of highly organized white matter have a high FA value, as 
seen in the corpus callosum, and areas without a preferred direction or 
structure, as seen in CSF, have a low FA value.  The direction of the white 
matter tracts can be displayed using the directional information and the 
anisotropy measures of the individual voxels.  This is known as tractography 







The other most common measure that can be calculated from the diffusion 
tensor is the mean diffusivity (MD).  MD gives average diffusion over all 
directions and is the same as the ADC.  For the most part, FA and MD are 
inversely related.  FA decrease and MD increase have been associated with loss 
of tissue integrity (117)(118). 
 
3.3.2.2 The	Assessment	of	White	Matter	Tracts	
There are a number of approaches to analyzing brain anatomy using DTI 
(122)(123).  In the Region of Interest (ROI) approach, specific ROIs are 
identified, either manually or via automated methods. DTI metrics, usually FA 
and MD, are then extracted from these ROIs and entered into statistical models 
(124)(125)(126).  The ROI method has the benefit of expert knowledge leading 
the identification of specific regions of interest in the brain, but there are a few 
limitations.  Manual tracing is very time consuming with the potential for  
variation of inter- and intra- user differences in the processing of images and 
identification of regions (122)(124)(125)(127).  Whole brain voxel based analysis 
(VBA) facilitates making statistical comparisons across the whole brain, 
without determining a priori ROIs.  In VBA, spatial normalization is performed 
by warping the individual image into a standard space and then performing 
voxel wise analysis.  The standard space template can be an average image of 
the whole group analysis, but is typically defined by the Montreal Neurological 
Institute (MNI) (128) atlas.  An example of DTI VBA is Tract Based Spatial 
Statistics (TBSS), which is implemented as part of the FMRIB Software Library 
(FSL) (129).  TBSS has been used in this thesis research (122)(130).  A further 
method of analyzing diffusion MRI is fiber tractography, which specifically 
identifies individual white matter pathways.  Tractography uses diffusion data 
to reconstruct white matter tracts in two ways; deterministic or probabilistic.  
Deterministic uses the principle direction of diffusion in each voxel to 
reconstruct the fiber pathways.  Probabilistic tractography uses probability 
distributions to reconstruct tracts (117)(131).   
 
Advanced MRI techniques are becoming popular in mTBI literature and the 
next chapter will review the body of literature and the current knowledge and 





There is considerable literature evaluating the white matter changes that occur 
after mTBI using diffusion MRI, but there is far less published data studying 
grey matter volume and cortical thickness post mTBI.  Overall there are only a 
few small studies looking specifically at structural changes post mTBI and the 
heterogeneity of these, both in TBI type and sample demographics, makes any 
consistent conclusions difficult. 
 
Tate et al. (132) studied twelve military personnel that had suffered blast 
injuries and sustained mTBI on average three months post injury.  Compared 
to a control group of their colleagues that did not have mTBI, there were 
statistically significant differences between the two groups with reduced 
cortical thickness in the superior frontal gyrus and the superior temporal gyrus 
in those that sustained blast mTBI.  However, this group also suffered 
audiology complaints such as hearing loss or tinnitus.  As the areas affected are 
involved in speech reception, the reduction in thickness could be due to the 
audiological damage rather than the mTBI injury, per se (132). 
 
Ling et al. (133) performed a prospective study with 51 mTBI patients matched 
with healthy controls and acquired structural imaging twenty-two days post 
injury, and did not show any significant difference in cortical thickness or 
whole brain volume between the mTBI and the control groups.  A smaller 
group of twenty-seven mTBI and matched controls returned at approximately 
four months post injury for repeat imaging and again there were no differences 
between the two groups (133).  One factor to take into account is the short time 
course from injury to scan time.  Perhaps four months is not long enough for 
cortical thickness or atrophy changes to develop.  Another study by Wang et al. 
(134) also used similar methods and looked specifically at cortical thickness.  
They found reduced cortical thickness in the mTBI group three months post 
injury in the left rostral middle frontal gyrus, but this group was small (n=11), 
and all the mTBI patients had been in an MVA as their mechanism for injury.  




Zhou et al. (135) followed 28 mTBI patients and 22 controls one year post injury 
and found significant structural changes in the mTBI group.  They found 
atrophy in the right precuneus.  The right inferior and medial orbital olfactory 
frontal regions also showed atrophy but this did not reach statistical 




Fractional anisotropy (FA) is the most common DTI metric in the mTBI 
literature (42)(113).  There is a mixture of findings, but the majority suggests a 
decrease in FA in white matter tracts after mTBI. The decrease in FA suggests a 
loss of normal neuronal architecture, indicative of axonal disruption or 
increased oedema within the white matter tracts or the perivascular spaces 
(123).  However many studies do not find any statistically significant 
differences post mTBI (42)(113)(123)(136)(137)(138).  Overall the heterogeneity 
of the literature in terms of groups definitions, scan protocols, time intervals 
and small sample sizes combined with a likely positive reporting bias makes 
me question the strength of the mTBI literature in this area. 
 
A quantitative literature review by Hulkower et al. (113) in 2013 looked at 100 
studies examining DTI in TBI of all severities with a combined patient number 
of 2337 subjects (113).  Abnormal FA in the corpus callosum was the most 
common abnormality in all methods of white matter tract analysis.  A 
subgroup analysis to separate findings by TBI severity was not performed and 
all severity mild-severe were analyzed together, which is a weakness of the 
review.  In 25 studies that used whole brain analysis, 17 showed abnormal FA 
in either the anterior/genu body or corpus callosum overall.  Abnormal FA 
was also reported in papers that used Region of Interest (ROI) and 
tractography.  Other areas of significant FA abnormality include the internal 
capsule, the fronto-orbital fasciculus, fornix, cingulum bundle and superior and 
inferior longitudinal fasciculus.  In 96 out of 100 studies, FA values were 
reduced in patients with TBI, with four of the studies finding elevated FA 
values (113).  While these four studies reporting increased FA may appear to be 
false positives, increased FA may be indicative of damage, specifically in areas 
of crossing fibres where a single fibre population is affected (139). 
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Hulkower et al. also looked at abnormal mean diffusivity (MD) and found 
similar results in the same anatomical white matter tracts observed for FA.  An 
interesting finding was in almost all ROI and tractography studies, MD values 
were abnormally low in mTBI relative to controls.  This seems counterintuitive 
given the findings of low FA.  On reviewing the supplementary table and some 
study references themselves which report high MD, I suggest this is most likely 
error and the findings mislabeled in the Hulkower paper.  Looking at several of 
the referenced studies, the reported change in MD should read as increased 
(140)(141)(142)(143).  Increased MD values months after mTBI could represent 
neuronal cell loss (144).  Thirteen studies that used whole brain analysis 
reported varying results but with a maximum of only six studies finding 
increased MD in analyses (113).  This further adds to the heterogeneity of the 
literature findings. 
	
Within the Hukower et al. quantitative analysis 72 of the studies looked at 
functional outcome of subjects and the relation to DTI findings.  Measures and 
methods of neuropsychological testing varied between studies, but overall, 
there was a positive correlation between cognitive measures and FA, and a 
negative correlation between cognition and MD.  With regard to general 
clinical outcomes, such as Glasgow Coma Scale (GCS), global outcome 
measures and Post-Concussion syndrome (PCS) symptoms, the majority again 
found a positive correlation with FA and negative correlation with MD (113), 
suggesting an underlying relationship between white matter health, cognitive 
measures, and clinical outcome 
	
A meta-analysis by Aoki et al. (123) in 2012 included 13 studies with a total of 
280 mTBI patients and 244 controls; 15 individual comparisons were 
investigated (123).  All studies used FA, but only seven reported on MD.  The 
corpus callosum showed a decrease in FA (p=0.023) and increased MD 
(p=0.015) compared to controls.  Specifically, when analyzing sub regions of 
the corpus callosum, only the splenium showed a significant decrease in FA 
(p=0.025) and increase in MD (p=0.0013) in the mTBI group relative to controls.  
The corpus callosum may be at increased risk of damage during mTBI in that it 
is the largest volume white matter tract in the brain, and the splenium may be 
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particularly vulnerable; the splenium’s posterior position adjacent to the 
immobile falx cerebri may make it more susceptible to shear/strain injury 
(105)(123). 
 
Aoki and Inokuchi (145) undertook a second meta-analysis published in 2016.  
The difference compared to their previous meta-analysis is that they performed 
a primary meta-analysis to analyze FA regional differences between control 
and mTBI in seventeen TBSS studies with 529 mTBI patients and 373 control 
patients (145).  The secondary analysis used whole brain voxel based and TBSS 
studies (583 mTBI patients and 414 controls patients).  Both the primary and 
secondary analysis showed reduced FA in three regions- the left thalamus 
extending into the splenium of the corpus callosum, the forceps minor and the 
superior longitudinal fasciculus (145). 
	
Khong et al. performed a systematic review of DTI and PCS in 2016 (138).  A 
literature search yielded 205 studies, of which 10 were included in the 
systematic review.  The study used PCS defined as “patients who experience 
persistent symptoms for 3 months or longer post-injury”(page 2) (138) and 
excluded studies that didn’t define PCS or mTBI or had fewer than six 
participants.  These 10 studies included 235 patients with PCS (141 male and 44 
female) and control groups were: orthopaedic injuries in one study, uninjured 
military controls in two studies, and the other seven studies used healthy 
controls.  DTI analysis methods included whole brain analysis in four, ROI 
analysis in four, and a voxel-wise approach to identify ROIs for ROI analysis in 
two studies.  The median time from injury to MRI scan was 20.5 months (range 
7 days to 259 months).  Seven out of the 10 studies used MRI data collected 
after the diagnosis of PCS, whereas three collected images in the acute stage 
before the development of PCS.  Thus, this review may be able to comment on 
the use of DTI as a diagnostic tool as well as a predictor of the development of 
PCS in the acute stage after the head injury.  Seven out of 10 studies found 
reduced FA in patients with PCS post mTBI compared to controls.  The most 
consistent finding was abnormal DTI metrics in the corpus callosum.  
However, three out of 10 studies did not find any changes in FA.  Seven studies 
reported increased MD and three did not.  Interestingly only one study found 
no change in either FA or MD.  The conclusion of this systematic review was 
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that “no DTI biomarker for PCS is identified due to the small body of research 
conducted on the topic and the heterogeneity of results reported” but it did 
conclude that “DTI abnormalities correlate with PCS incidence and symptom 
severity” (138). 
 
A systematic review by Dodd et al. (146) in 2014 evaluated 31 studies for the 
diffusion findings but also looked at clinical and methodological factors that 
could influence results in semi-acute mTBI patients (146).  While 13 studies 
showed reduced FA, 11 reported increased FA, two reported bidirectional 
finding and five reported no significant change in FA.  The pertinent outcome 
from that systematic review is that chi squared analyses showed the “total 
number of diffusion images was significantly associated with findings of either 
increased (DW>30) or decreased (DW<25) anisotropic diffusion” (146).  Year of 
publication and mTBI sample size were not associated with an increase or 
decrease in FA (p=0.10) (146).  
	
4.2.2 Variability	in	the	literature	
The large variability in the findings of advanced imaging in mTBI in the 
literature may be due to several factors.  The lack of a unifying single definition 
of mTBI or PCS has resulted in considerable heterogeneity of patient samples, 
making the identification of relevant imaging markers more difficult.  Other 
differences in baseline demographics such as age, sex, and education level has 
also influenced findings.  The different mechanisms of injury potentially 
introduced confounding into studies as pathophysiology has been presumed to 
be the same despite different mechanisms.  Study sample sizes have also 
typically been small, leading to limitations in generalizing from these results.  
Differences in MRI scanners, e.g. 1.5T vs 3T, image acquisition, and also the 
time from injury to the time of scan are other important variables that lead to 
heterogeneity in the literature (113)(123)(146). 
 
Timing of the MRI scan in relation to the time from the injury is important as 
the pathophysiology is different across the time period.  For example, in the 
acute phase in the days after injury, there is disruption to neuronal 
architecture, cytotoxic oedema, and neuronal swelling, which subsides over 
time.  Increased FA initially may represent these changes whereas increased 
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MD values months after mTBI could represent neuronal cell loss (42)(116)(144).  
The differences in timing of the MRI scan in the disease process can also vary 
between studies and make direct comparisons difficult.  The control group 
used for comparison can also introduce potential confounds; appropriate 
control groups are vital to move TBI research in a positive direction.  In many 
cases, controls may not have been exposed to trauma itself and therefore brain 
changes could be because of the stress of the trauma, rather than the TBI itself 
(113)(14).  It is expected that findings will vary depending on whether TBI 
patients are compared to perfectly healthy controls, controls who have 
experienced a TBI but who have recovered well, controls who have 
experienced some sort of non-cranial injury, or those who have some other 






The work presented within this thesis is part of a larger mixed methods 
exploratory study into mTBI, with emphasis on chronic PCS symptoms and 
early identification of at risk individuals.  The long-term aim of the broader 
study is to identify methods capable of selecting patients at risk of developing 
PCS in order to implement early intervention strategies to improve outcomes 
after mTBI. 
 
Ethical approval has been given by the Upper South A Regional Ethics 
Committee reference URA/12/05/015/AM10 (see Appendix). 
	
5.2 Aims/hypotheses	
The global aim of this thesis is to explore structural and diffusion MRI 
techniques in relation to mTBI and PCS.  Specifically, I will ascertain whether 
structural and DTI brain measurements differ in the PCS group compared to 
the non-PCS and control groups.  In this way this thesis may provide relevant 
information on methods capable of predicting development of PCS, which may 
ultimately lead to improved management of resources and services for those at 
risk of developing PCS. 
 
I hypothesize that there will be structural and DTI changes in the PCS group 
compared to non-PCS and controls.  Hence the null hypothesis is that there will 
be no MRI differences between the PCS group compared to non-PCS and 
controls. 
 
As a secondary analysis I will review the mTBI group, both PCS and nonPCS, 
as one group to investigate the relationship between MRI and outcome 





Data previously collected from 138 participants were used for this study.  This 
section describes the recruitment sources for each of the four study groups.  
The two mTBI and chronic pain participant groups were part of a Health 
Research Council funded study conducted at Burwood Hospital, Christchurch, 
New Zealand.  mTBI was defined using the New Zealand Guidelines Group 
criteria set (2) and participants with mTBI were recruited from the Concussion 
Clinic at Burwood Hospital.  Forty-two subjects met ICD-10 criteria for PCS 
and comprised the PCS group.  Thirty subjects deemed fully recovered from 
mTBI comprised the non-PCS group. There were two control groups used for 
comparison against the PCS and non-PCS groups. The first comprised a group 
of 25 subjects recruited from the Pain Management Service at Burwood 
Hospital.  Chronic pain (Chronic Pain Syndrome) was diagnosed by each 
participant’s treating physician.  In addition for the MRI analysis a group of 41 
healthy control participants were recruited from other ongoing studies at the 
New Zealand Brain Research Institute (NZBRI)- these participants were not 
part of the original mTBI study additional ethics approval was obtained (see 
Appendix).  The PCS, non-PCS and CP groups were all matched for age, 
gender, education, injury, severity and pre-injury work status.  The healthy 
control group was matched only for mean age and sex distribution as 
education and work status were not acquired (as they were not part of the 
original study) and there was no injury.  Group demographics are displayed in 
Table 5.1. 
 
Sample size in our study (PCS=42 and Non-PCS=30), and α=0.05, there was 
80% power to detect a difference in means of d=0.67 (two-tailed).  The original 
study was PCS and non PCS and CP group and this was studied on the PCS vs 
non-PCS group. 
 
In the mTBI groups (PCS and non-PCS), Glasgow Coma Scale (GCS) was 
acquired at the time of first acute presentation to medical services, i.e. at 
Emergency Department presentation; similarly, the time spent in Post 
Traumatic Amnesia (PTA) was also recorded (in days).  The mechanism of 
injury was not collected.  The time from injury to the time of the MRI scan (in 
months) was also collected for the mTBI groups, and where applicable, this 
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was also obtained for the chronic pain group.  The PCS, non-PCS and CP 
groups all underwent neurocognitive testing including: the Repeatable Battery 
Assessment of Neuropsychological Status (RBANS), which tests across five 
different cognitive domains and then provides an overall total score (147).  This 
test is administered over 20-30 minutes by a trained psychologist (148); the 
Colour Word Interference Test (CWIT) from the D-KEFS Battery (149), which 
measures ability to inhibit a dominant automatic verbal response, speeded 
cognitive processing and cognitive flexibility.  Four scaled scores can be 
calculated; the Rivermead Post-Concussion Symptom Questionnaire (RPQ), 
which is written self-assessment  tool used for diagnosis and to assess severity 
of mTBI symptoms (150); Hospital Anxiety and Depression scale (HADS A and 
HADS D), another written self-assessment is used to assess severity of anxiety 
and depressive symptoms (151). The healthy control group did not undergo 
neurocognitive testing and were only included for the MRI analyses. 
 
Differences in the clinical data, symptoms and neurocognitive scores across the 
two mTBI groups were assessed using one way ANOVAs, with post-hoc 
pairwise comparisons; p<0.05 was considered significant. 
 
Table	5-1		Study	sample	demographics	
 PCS Non-PCS CP Controls 
Number 42 30 25 41 
















40 50 70 70 
Time of injury to 
scan (months) 
30.9 (SD) 37.6 (SD) NA NA 
	
5.4 MRI	acquisition	
All imaging was performed at Hagley Radiology on a 3T General Electric HDxt 
scanner (GE Healthcare, Waukesha, WI) with an 8-channel head coil.  Subjects 
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were given ear plugs and/or headphones and asked to remain as still as 
possible during the examination. 
 
Structural MRI images were acquired using a high resolution volumetric T1-
weighted sequence and DTI images, with a 2D diffusion-weighted, spin echo, 
echo planar imaging sequence, with diffusion-weighting in 64 uniformly 
distributed directions, and 8 images without diffusion-weighting.  Details of 
the image acquisition are detailed below in Table 5.2. 
 
Table	5-2		MRI	image	acquisition	parameters	
 T1-weighted image Diffusion 
Pulse name SPGR Spin echo EPI 
Imaging mode 3D 2D 
Imaging plane Axial Axial 
Repetition time (TR) 6.7ms 86.4ms 
Echo time (TE) 2.8ms 13,000ms 
Inversion time (TI) 400ms NA 
Flip angle 15° 90° 
Field of view 250mm 240mm 
Slice thickness 1mm 3mm 
Gap (between slices) 0 0 
Matrix 256×256 128×128 
Voxel size 0.98×0.98×1mm3 1.88×1.88×3mm3 
Number of slices 170 48 
Coverage Whole brain Whole brain 
Parallel imaging ASSET - 
Acceleration factor 1.5 - 
Scan time (minutes) 5:07 7:09 




(b value= 0) 
NA 8 






Image segmentation was performed using SPM12 (Statistical Parametric 
Mapping, Wellcome Department of Imaging Neuroscience, The Institute of 
Neurology, London, UK) in Matlab 2015a (Mathworks, Massachusetts, USA 
2015).  SPM is a software package designed for the analysis of brain imaging 
data, providing a common framework for image processing and analysis. SPM 
implements a general linear model and uses a voxel-based approach to analyze 
the entire brain.   
 
The T1 weighted structural image for each individual was segmented into grey 
matter (GM), white matter (WM), and cerebral spinal fluid (CSF). We then ran 
DARTEL (existing template) using the template provided with the VBM8 
toolbox (in MNI space, http://dbm.neuro.uni-jena.de/vbm/).  GM segments 
were then normalized using the DARTEL flow fields, modulated, and 
smoothed (8 mm FWHM).  Lastly, a GM mask was created by averaging all 
smoothed normalized, modulated GM segments, thresholding at 0.15.  
 
A Matlab script was created to calculate the volume of GM, WM and CSF 
segments for each subject (in subject space).  Total intra cranial volume (ICV) 
was calculated as the sum of the GM, WM and CSF segments; ICV was used as 
a covariate in later analyses.  
	
5.5.1.2 Cortical	thickness	
Automated cortical thickness measurements were performed using Freesurfer 
(version 5.3; available at: http://surfer.nmr.harvard) (111).   
 
Pre-processing of T1 images included: removal of tissue outside the brain from 
the images, transforming to automated Talairach space, intensity 
normalization, defining the grey/white matter boundary, correction of 
topology and placement of the grey/white matter and grey matter/ CSF 
boundaries.  Each step was performed independently for each subject.  Cortical 
thickness is calculated as being the distance between grey/white matter and 
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grey matter/CSF boundaries.  Next all surface models in each individual 
subject were manually inspected to ensure accurate tracing had been 
performed.  The subject template was loaded and opened in Freeview (an 
imaging viewer programme) and then each of the left and right pial surfaces 
and left and right white matter outlines were overlaid and inspected for each of 
the 138 subjects.  There were no significant anomalies in the tracing and hence 
none required manual correction.  Cortical maps were smoothed using a 
circularly symmetric Gaussian kernel across the surface with a full width at 
half maximum (FWHM) of 10 mm. 
	
5.5.2 DTI	
MR image pre-processing and statistical analyses were performed using tract-
based spatial statistics (TBSS) in FSL 5.0 (www.fmrib.ox.ac.uk/fsl).  Correction 
of motion- and eddy current distortion on the DWI images was performed.  
Using DTIFIT the diffusion tensor was then calculated at each voxel, producing 
fractional anisotropy (FA) and mean diffusivity (MD) images.  Then the brain 
extracted using BET.  The FA images were matched to a common space 
(FMRIB58 FA template) using the nonlinear registration tool FNIRT.  The mean 
FA image was thinned (FA 0.2) to create a mean FA skeleton that represented 
the middle of all tracts common to the group.  Each subject’s aligned FA image 
was then overlaid onto this common skeleton image.  This step minimizes 
misalignment that is prevalent in standard DTI registration procedures.  To 
create a separate skeleton representing MD values, the nonlinear warps and 




One way ANOVAs, implemented in R (version 3.3.1), running from R studio 
(Boston, MA, USA), were used to test for statistically significant differences in 
demographics, clinical measures (GCS, PTA), and neurocognitive measures 
(HADS, RPQ) across the groups (PCS, Non-PCS, CP and Controls).  Significant 





Smooth, modulated and normalized grey matter images were entered into an 
ANCOVA model in SPM to assess differences in grey matter volume across the 
PCS, Non-PCS, CP and Control groups, with age, sex and ICV as covariates. 
Contrasts allowing investigation of pairwise comparisons between all four 
groups were tested (Table 5.3). 
 
In a sub group analysis restricted to participants that had experienced a mTBI 
(i.e. the PCS and non-PCS groups), a series of multiple regression models were 
performed to investigate the relationship between grey matter volumes and (1) 
GCS, (2) PTA, (3) HADS A, (4) HADS D, (5) RPQ, (6) RBANS TS, (7) CWIT III 
and (8) CWIT IV with age, sex, and ICV as covariates.  
 
5.6.2.1.1 Multiple	Comparisons	
With MRI data, each subject volume contains on the order of a few 100,000 
voxels.  As separate hypothesis tests are performed at each voxel, high false 
positive (a error) rates can lead to inaccurate statistical results.  For example, 
using a voxel-wise a value of 0.05, where you would expect 5 false positive for 
every 100 tests, suggests a total of 5,000 false positive results, which are 
indistinguishable from true positives.  To limit the likelihood of obtaining these 
high false positive results, we can correct for multiple comparisons by one of 
two ways: Family-wise error rate (FWE), which is the likelihood of obtaining at 
least one false positive in a family of tests; or False discovery rate (FDR), which 
is the proportion of false positive results among all the significant results.  At 
the level 0.05, we know 95% of results are likely to be true and no more than 
5% of the voxels above the threshold will be false positives.  However again, 
we still won’t be able to determine which are the truly correct and which are 
the false positives (152).  Hence, cluster-wise FDR will be used to correct for 







  PCS Non-PCS CP Controls 
1 PCS>non-PCS 1 -1 0 0 
2 PCS<non-PCS -1 1 0 0 
3 PCS>CP 1 0 -1 0 
4 PCS<CP -1 0 1 0 
5 PCS>controls 1 0 0 -1 
6 PCS<controls -1 0 0 1 
7 Non-PCS>CP 0 1 -1 0 
8 Non-PCS<CP 0 -1 1 0 
9 Non-
PCS>controls 
0 1 0 -1 
10 Non-
PCS<controls 
0 -1 0 1 
11 CP>controls 0 0 1 -1 







The same pairwise group comparisons were investigated for cortical thickness 
as were for grey matter volume.  That is, each group was compared to every 
other group; PCS >Non-PCS, PCS>CP, PCS>controls, Non-PCS>CP, Non-
PCS>Controls and CP>Controls, in both the left and right hemispheres.  Again 
age, sex, and ICV were included as covariates.  
 
For the cortical thickness comparisons, I used a cluster-wise correction for 
multiple comparisons employing the precomputed Z Monte Carlo simulations, 
with an initial voxel-wise, cluster forming threshold of z=3 (p=0.001), to 
provide cluster-wise correction for multiple comparisons.  Results were 
thresholded at a corrected p<0.05 (Z>1.3).  We accounted for testing in both 
hemispheres.  In 2016, Eklund et al. (153) published a mass empirical analysis 
of 3 million random group analyses from various software packages, such as 
FSL and SPM, to calculate empirical familywise error rates.  Based on this 
work, in this study, I used an initial voxelwise/cluster-forming threshold of 
z=3 (p<0.001) in order to avoid inflated false positives when correcting for 
multiple comparisons.   
 
5.6.3 DTI	
Voxel-wise statistics on the skeletonized images (first FA, then MD) were 
performed using a permutation-based inference tool in FSL for nonparametric 
statistical thresholding (“randomise”).  The same group differences were then 
assessed (PCS, Non-PCS, CP and Control) with age, sex, and relative motion 
during the DTI scan as covariates.  As before, I specifically looked at pairwise 
comparisons between all individual groups.  For each contrast, the null 
distribution was generated over 5,000 permutations and the a level set at p < 
0.05, corrected for multiple comparisons (family-wise error correction using 





One way ANOVA for age showed no statistically significant differences across 
the four groups.  Pearson‘s Chi-squared test for gender was performed and no 
relationship was found between groups (p=0.09).  See table 1. 
 
Within the TBI groups, GCS and PTA scores were not significantly different 
between the PCS and non-PCS groups.  However, the PCS group had 
significantly higher scores on RPQ (T= 9.1), HADS Anxiety (T= 2.4), and HADS 
Depression (T=2.9), than the non-PCS group (p<0.05).   
 
Post hoc Tukey’s HSD tests revealed that the non-PCS group had statistically 
significant lower scores in RPQ, HADS A and HADS D compared to the CP 
groups (p<0.05).  The PCS group and the CP group had no statistically 
significant difference between HADS A or HADS D.  With respect to RPQ 
scores, the PCS groups scored slightly higher but comparison between the PCS 
and CP groups neared but did not reach significance with p=0.058.  Analysis of 
neurocognitive tests found CWIT IV time for completion was higher in PCS 
compared to Non-PCS (p <0.05).  RBANS and CWIT III showed no significant 
difference between PCS and non-PCS groups.  The time interval between injury 
and scan was not statistically significant T=0.56 and p= 0.58 (Tables 6.1 and 
6.2).   
	
Table	6-1		Study	sample	demographics	
 PCS Non-PCS CP Controls 
Number 42 30 25 41 
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Table 6.3 presents summary MRI metrics, including total grey matter volume, 
total white matter volume, total CSF volume, total intracranial volume, and 
absolute and relative motion during the diffusion acquisition.  Absolute motion 
is the movement of the head in an image compared to the first image and 


























































One way ANOVA showed no statistically significant difference between 
groups in grey matter, white matter, CSF or ICV.  Age and sex were covariates. 
 
6.2.1 Grey	Matter	Volume	
No significant statistical voxelwise differences were found in grey matter 
volume between the PCS or the Non-PCS groups compared to controls.  The 
CP group compared individually with all other groups, that is PCS, Non-PCS 
and controls, showed reduced grey matter volume in the cerebellum (Figures 
6.1, 6.2, 6.3).  These findings were particularly localized to the inferior 
cerebellar peduncles, vermis and cerebellar tonsils.  The cerebellar grey matter 

















Within the whole mTBI group (restricted to only PCS and Non-PCS), no voxels 
survived correction for multiple comparisons when investigating the 
association between grey matter volume and any of the following: GCS, PTA, 
HADS A, HADS D, RPQ or CWIT III and IV.  There was positive association 
between grey matter volume and RBANS total score which can be interpreted 
as a reduction in grey matter volume in the left cerebellum in the mTBI group 
with lower RBANS scores (Figure 6.4).  There were no differences between the 









There were no statistically significant differences in cortical thickness between 
any of the groups.  The cortical thickness analysis included only supratentorial 
cortex.  Given grey matter volume reduction was observed in the cerebellum in 
the CP group, an infratentorial finding, the cortical thickness result is consistent 




The mean white matter skeleton mask was overlaid on the study specific mean 
FA and inspected visually.  Its shows normal anatomy of the white matter 
tracts, which is useful as it gives confidence in the methods and results 








The PCS group and non-PCS group showed no significant differences in FA or 
MD relative to controls, nor were there differences between the PCS and non-
PCS groups in FA or MD.   
	
Analysis within the whole mTBI group (restricted to only PCS and Non-PCS) 
found a positive association between CWIT IV and FA.  That is the higher the 
CWIT IV score, the higher the FA (TFCE-corrected p<0.05).  These findings 
were evident in the corpus callosum, the internal and external capsule and the 
cerebral peduncle (Figure 6.6).  There were no changes in MD.  There were no 









The CP group showed statistically significant reduction in FA (TFCE-corrected 
p<0.05) compared to the Control group in bilateral thalami and the body of the 
right corpus callosum.  In the comparisons between CP and the PCS and Non-
PCS groups some findings neared significance but did not meet the corrected 
p<0.05 threshold.  With regard to MD, there was a statistically significant 
difference (TFCE-corrected p<0.05) between the CP and control group, with 
increased MD in multiple white matter tracts in both cerebral hemispheres and 
within the brainstem (p<0.05). 
 
6.3.2.1 Anatomy	of	CP	findings	
The significant reduction in FA in the CP vs control group occurred within the 
left and the right thalamus and within the body of the right corpus callosum 


















Increased MD in the CP group compared to controls occurred in many white 
matter tracts.  Anatomically these areas of increased MD started from the 
brainstem, included both thalami, internal capsules (anterior and posterior 
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limbs) and the external capsule, right more than left.  The corpus callosum was 











With the difficulty of studying in vivo human models of mTBI, advances in 
neuroimaging and software design are emerging areas of brain research.  In the 
absence of macroscopic neural damage, it therefore follows that microstructural 
changes result in damage to the cell or disruption of physiological function 
leading to ongoing neurological signs and symptoms after the initial 
biomechanical force.  These are likely multifactorial or a series of interrelated 
events, whatever the pathophysiology; metabolic, vascular/loss of 
autoregulation, damage to the blood brain barrier, inflammatory/immune 
mediated responses and neuronal damage, and have not been visible on 
traditional imaging techniques of CT or MRI.  If such brain changes exist 
advanced MRI techniques such as the ones used in this study may detect such 
microscopic changes or their sequelae and this provides another area to direct 
future research into injury prevention and therapeutic treatment. 
	
In this study, I used structural (T1- weighted) and diffusion tensor imaging 
(DTI) to investigate grey matter atrophy, cortical thickness, and white matter 
integrity across four participant groups: PCS, non-PCS, CP, and healthy 
controls.  There were no significant differences in brain volume, cortical 
thickness, or DTI metrics along the centres of principal white matter tracts 
between the PCS and non-PCS groups, nor when these two mTBI groups were 
compared to controls.  However, the CP participants exhibited reduced 
cerebellar grey matter volume relative to all three groups (PCS, non-PCS, and 
healthy controls) and significant reduction in FA and increased MD in several 
white matter tracts.  There were no cortical thickness differences in any group.  
 
7.1 	Demographic	and	Clinical	Characteristics	
Groups were well matched for age and gender.  This helps reduce the potential 
impact of age and gender on results. 
 
The PCS group had significantly higher scores on RPQ, HADS Anxiety (HADS 
A) and HADS Depression (HADS D) than the non-PCS group (p<0.05).  This is 
an expected finding.  In particular, the PCS groups had higher post concussive 
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symptom scores than the recovered non-PCS group because self-reported 
symptom burden was used to determine group membership.  This finding 
supports published research that demonstrates increased risk for depression 
and anxiety in populations demonstrating chronic health symptoms such as 
PCS (85).  These findings also support the allocation of patients to the correct 
groups and enhance the strength of comparisons between the two groups.   
 
Analysis of neurocognitive test results found CWIT IV time to completion 
scores were on average higher in the PCS compared to Non-PCS group (p 
<0.05) but there were no other significant findings between the groups.  This 
suggests the PCS groups were slower on average to complete the task, and this 
would be consistent with slower cognitive processing.  RBANS total scores and 
CWIT III scores were not significantly different between the PCS and non-PCS 
groups.  This suggests that while self-reported symptom scores were 
significantly different between the two groups, there were only small 
differences between the groups regarding objective cognitive test scores.  The 
CWIT-IV task evaluates higher level attentional control (149) and these findings 
could be suggestive of differences between the groups in the attention domain.  
However these findings could also be explained by the overlay of depression 
and anxiety as demonstrated by HADS scores. 
 
The non-PCS group had significantly lower scores across RPQ, HADS A and 
HADS D compared to the CP group (p<0.05).  The PCS group and the CP 
groups were similar and had no significant differences in their HADS A or 
HADS D scores.  The PCS group had slightly higher RPQ scores than the CP 
group though the groups neared but did not reach significance with p=0.058.  
This is useful as it shows significant similarities in the clinical and psychosocial 
nature of the PCS and CP groups, which might make MRI findings, especially 
if similar, very interesting.  However as discussed in the results section I found 
no brain changes, structural or DTI, in the PCS group compared to controls, 
and rather there was a significant difference between the PCS and CP groups in 
the reduction of cerebellar volume in the CP group compared to the PCS 





No significant statistical voxelwise differences were found in grey matter 
volume or cortical thickness between the PCS and the Non-PCS groups or 
compared to the control groups, which is not consistent with the majority of the 
published literature.  While there are a few of studies which have reported 
atrophy and cortical thinning (134)(135)(133), one significant complication with 
the mTBI advanced MRI literature findings is that the study sample sizes are 
generally small.  In this study, the sample size is robust compared to other 
studies, providing more statistical power.  In total, 138 subjects were recruited 
for this study (42 PCS, 30 Non-PCS, 25 CP, and 41 healthy controls).  
 
Within mTBI research there are several definitions and mechanisms of injury 
that may affect pathophysiology.  While it is difficult to select patients based 
solely on the mechanism of injury, in this study other group demographics 
were well matched.  The PCS, non-PCS and CP groups were all matched for 
age, gender, education, injury, severity and pre-injury work status.  The 
healthy control group was matched for mean age and gender distribution.  
Likewise within the TBI groups, GCS and PTA scores were not significantly 
different between the PCS and non-PCS groups.  This is a strength of the study 
as it shows that at baseline, or the time of injury, all characteristics were similar 
between the two groups.  Therefore, ‘injury severity’ per se should have a 
minimal effect on the results of the study.  Injury mechanism data was not 
collected, similar with other literature, but this could influence the 
pathophysiology of mTBI and result in different outcomes. 
 
Another confounding factor may be the time between injury and MRI.  Some 
studies suggest that a scan too close to the time of injury may miss brain 
changes that occur much later after injury (133)(146).  This was most likely not 
the case in this study, as the mean time of injury to MRI 30.9 months in the PCS 
group and 37.6 months in the non-PCS group.  Perhaps also the time period 
from injury to scan was too long in my study- this will be discussed in the DTI 
section below.  A further complication with interpreting the literature is 
heterogeneity, including both heterogeneity of injury and heterogeneity of 
patient groups (age, sex, etc.).  However, with a good sample size and well-
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characterized groups, this study’s lack of significant structural differences 
between PCS and Non-PCS groups still adds knowledge to the current body of 
literature on the topic. 
 
The only significant structural finding from the mTBI group came in analysis of 
the PCS and Non-PCS groups as a single mTBI group.  There was a positive 
association between grey matter volume and RBANS total score which can be 
interpreted as a reduction in grey matter volume in the left cerebellum in the 
mTBI group with lower total RBANS total scores.  But again, there was no 
significant difference between the PCS and Non-PCS groups in grey matter 
volume.  RBANS is a neurocognitive test that evaluates performance across five 
cognitive domains; immediate memory, visuospatial/constructional, language, 
attention and delayed memory (147).  For this analysis the RBANS total score 
was used.  This is because the total score has been shown to be the most robust 
of the RBANS indices in TBI samples (155).  It is unclear why there are only 
slight cerebellar changes in the mTBI group.  This is unusual as these higher 
cognitive tasks are supratenotrial in anatomical basis.  It is possible this might 
represent modulation or processing of information in descending tracts.  These 
findings are discussed further in section 7.4. 
 
7.2.2 Structural	Imaging	in	CP	Discussion	
The CP group compared with all other groups, that is PCS, Non-PCS and 
controls, showed reduced grey matter volume in the cerebellum.  These 
findings were particularly localized to the inferior cerebellar peduncles, vermis 
and cerebellar tonsils.  The cerebellar grey matter reduction was most extensive 
and had the largest T values in the CP < control comparison; the PCS group 
had the least amount of reduction in volume when compared to the CP group.  
This is a very interesting finding.  Looking at other CP research into grey 
matter volumes, and even in DTI, there are only a handful of papers that have 
reported reduced grey matter volume in the cerebellum, as most studies focus 
on cortical changes (87)(89).  The first study was Rodriguez-Raecke (2013) who 
investigated 20 patients with unilateral chronic hip pain due to osteoarthritis.  
This group monitored structural changes up to a year post hip replacement.  
Initially they found reduced cerebellar volume pre-operatively.  Post 
operatively, after resolution of pain, the grey matter changes in the cerebellum 
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increased (87).  This either suggests that the changes in chronic pain are not 
neuronal atrophy or brain damage and that these changes are, to some degree, 
reversible.  But also worth considering in this context is that as a patient 
becomes more mobile after hip replacement, compared to pre-operative levels, 
the increased motor function after hip replacement could also contribute to 
these structural changes.  An fMRI study by Zambreanu (2005) used healthy 
volunteers and showed significantly increased activation in the contralateral 
brainstem, cerebellum and other supratentorial locations during hyperalgesia.  
The brainstem activation was localized to the midbrain reticular formation and 
the periaqueductal grey matter suggesting that these areas are involved in 
central sensitization or descending control of pain (89).  These areas were 
involved in the reduction of grey matter volume in this study; hence, my 
results support this earlier published work in describing the role of the 
cerebellum in processing of chronic pain, specifically as a relay system.  
Similarly, cerebellar differences are supported by my DTI findings, to be 
discussed later.  
 
Significant grey matter findings elsewhere such as the cingulate cortex, 
orbitofrontal cortex, insula and operculum and dorsolateral prefrontal cortex 
have been found and widely reported in chronic pain (76)(91)(90).  These 
anatomical areas are all part of the supraspinal nociceptive processing.  Despite 
this published evidence of reduced grey matter in the supratentorial 
anatomical areas listed, I did not find such results in this study.  This was 
repeated in my cortical thickness analysis, where there were no statistically 
significant differences in supratentorial cortical thickness between any of the 
groups.  Given grey matter volume reduction was observed in the cerebellum 
in the CP group, the supratentorial cortical thickness result is consistent with 
the volumetric grey matter volume results.  While the volumetric and thickness 
analyses showed a consistent null result in supratentorial regions in the current 
study, it is surprising that no other atrophy or thinning was found in the CP 
group.  Perhaps this is due to the small number of chronic pain patients (n=25) 
in this study, or the cause or type of chronic pain in this study wasn’t defined 
as rigorously as in other studies. 
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Given the current cerebellar findings, it would be interesting to investigate 
whether the CP patients demonstrated any clinical signs of cerebellar 
dysfunction, such as ataxia.  This was not explored in this study, but maybe an 
area of future work.  Comparison of the CP patients and their clinical 
examination, in terms of cerebellar signs, compared to other groups with 
reduced grey matter volume in the cerebellum, such as those with stroke or 




The only significant finding with the mTBI group and DTI came in the analysis 
of the whole mTBI group (restricted to only PCS and Non-PCS) which found a 
positive association between CWIT IV scores and FA in the areas of the corpus 
callosum, the internal and external capsule and the cerebral peduncle.  That is 
the higher the CWIT IV score, the higher the FA (TFCE-corrected p<0.05).  
These findings did reach statistical significance, but the reason why they were 
not found in CWIT III or RBANS is interesting and makes the interpretation of 
this difficult.  There were no association changes in MD relating to CWIT IV 
and no significant findings with the CWIT III scores or RBANS total score in 
FA or MD in the mTBI group.   
 
The PCS group and non-PCS group showed no significant differences in FA or 
MD relative to controls, nor were there differences between the PCS and non-
PCS groups.  This negative finding does not support the majority of published 
literature on the topic.  A quantitative literature review by Hulkower et al. in 
2013 looked at 100 DTI in mTBI articles with a combined patient number of 
2337 subjects (113).  In 96 out of 100 studies, FA values were reduced in 
patients with mTBI, with four of the studies finding elevated FA values.  
Abnormal FA was most commonly found in the corpus callosum with other 
areas including the internal capsule, the fronto-orbital fasciculus, fornix, 
cingulum bundle and superior and inferior longitudinal fasciculus.  By this 
comparison, perhaps the lack of statistically significant FA differences in my 
study are the most surprising.  This further adds to the heterogeneity of the 
literature findings.  A surprising finding was in almost all ROI and 
tractography studies, MD values were abnormally low in mTBI relative to 
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controls.  As mentioned previously, on reviewing some of the referenced 
literature I suggest this is most likely an error and the findings mislabeled in 
the Hulkower paper.  Looking at several of the referenced studies the reported 
change in MD should read as increased (140)(141)(142)(143).  With regard to 
whole brain analysis, thirteen studies that used this method, had varying 
results but with a maximum of only six studies finding increased MD in 
analyses (113).  As mentioned previously, sample size in this study was 
adequate.  With the sample size in our study (PCS=42 and Non-PCS=30), and 
α=0.05, there was 80% power to detect a difference in means of d=0.67 (two-
tailed).  Comparably sized studies in the literature have found positive results 
but given this power calculation perhaps this study was under powered and 
this could explain the lack of identifiable statistically significant results. 
 
Additionally, different methods may help to explain the difference with the 
literature.  In addition to smaller groups, many studies use different definitions 
of mTBI and PCS, which complicates interpretation across studies.  Other 
studies employed older 1.5T MRI scanners; many found positive results.  
Perhaps the 3T scanners would improve the significance of findings.  The time 
between injury to time of scan also varies significantly between studies, with 
some suggestion that FA/MD change in the acute to chronic stages.  The mean 
time from injury to MRI-30.9 months in the PCS group and 37.6 months in the 
non-PCS group-is at the longer end of the time interval compared to other 
studies and perhaps this influenced my results.  Perhaps I missed acute results 
or perhaps after two years, for example, the healing has occurred and the 
changes have resolved or become undetectable.  A prospective study following 
mTBI from acute to chronic state with serial imaging over a long period would 
be a good future study as it would include potential acute injury changes and 
also stage any changes over time to help develop a picture of pathophysiology 
over time. 
 
One study did agree with my negative DTI findings.  Lange et al. (2012) 
studied 60 mTBI patients (21 PCS and 39 non-PCS) and 34 controls and found 
no difference in DTI measures.  However the time from injury to time of scan 
was only 6-8 weeks, which differs significantly from my study interval (137).  
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Also, the published literature could represent positive reporting bias, though 
there is no way to confirm this.   
 
I have employed Diffusion Tensor Imaging (DTI) in this study, which produces 
a diffusion tensor in each voxel of the brain.  The diffusion tensor presumes 
that there is only one single type of fiber in each voxel, which is not always the 
case.  For example, there can be fibers of different directions or crossing fibers 
within a single voxel.  These factors can mean that white matter tracts could be 
misrepresented.  To combat this new techniques such as High Angular 
Resolution Diffusion Imaging (HARDI) and diffusion kurtosis imaging have 
been developed, which may provide more accurate information on the 
microstructural mTBI changes, if present (125)(156)(157).  
 
Overall the heterogeneity of the literature in terms of group definitions, scan 
protocols, time intervals and small sample sizes combined with a possible 
positive reporting bias raises questions about the strength of conclusions that 
can be drawn from the mTBI literature.  Newer techniques such as HARDI and 
diffusion kurtosis may be the next step in the future of diffusion research in 
mTBI.   
 
7.3.2 DTI	Imaging	in	CP		
The CP group showed significant reduction in FA (TFCE-corrected p<0.05) 
compared to the Control group in bilateral thalami and the body of the right 
corpus callosum.  The CP group also tended toward FA differences when 
compared to the PCS and Non-PCS groups, but these did not survive 
correction for multiple comparisons.  The reduced FA in the thalami and the 
right corpus callosum in the CP group compared to controls support the 
findings in the published literature. 
 
With regard to MD, there was a significant difference (TFCE-corrected p<0.05) 
between the CP and control group, with increased MD in multiple white 
matter tracts from the brainstem, included both thalami, internal capsules 
(anterior and posterior limbs) and the external capsule, right more than left.  
The corpus callosum was affected bilaterally, but the right more so than the 
left.  Again, the changes in these locations support the findings in published 
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literature.  Research into CP using other neuroimaging modalities such as 
fMRI, PET, MEG and EEG has shown several areas of the brain involved in the 
pathophysiology of pain.  The anterior cingulate cortex, insula, frontal cortices, 
somatosensory cortices, thalami and amygdala are the supratentorial 
anatomical areas involved in the processing and modulation of pain.  The 
brainstem, particularly the periaqueductal grey matter and the brainstem 
reticular formation play a role in the descending regulation of pain (89) 
(91)(90).  It is significant that the FA/MD findings in this study can be 
explained by the relationship of white matter tracts in some of these areas 
given their role in the pathophysiology of processing and modulation of pain. 
 
Advanced MRI is becoming much more frequently used to investigate chronic 
pain, and is changing the way CP syndrome is viewed.  Given the significant 
brain changes in this condition detected using fMRI, PET, MEG and EEG, in 
addition to structural and DTI techniques (89)(90)(91)(88)(93)(95), it is now 
thought that CP is an organic disease rather than being purely a psychosocial 
syndrome.  The other side of the CP brain changes debate is what comes first: 
are the brain changes the cause of the chronic pain or are they adaptive changes 
that have occurred after the development of the syndrome?  This question may 
now be investigated with brain imaging.  For example, reversible brain changes 
have been reported after hip joint replacement (87)(76)(86).  Another 
prospective study using MRI techniques at multiple points over time may help 
to answer this question.   
 
7.4 	Findings	within	the	mTBI	groups	and	Neurocognitive	tests	
An interesting outcome of this study is firstly, the structural imaging finding of 
a positive association between grey matter volume in the mTBI group 
(combined PCS and Non-PCS groups) and the RBANS total score and 
secondly, the positive findings in the DTI analysis of CWIT IV and FA.  Again, 
there were no MRI differences between either PCS and Non-PCS and the 
healthy control groups.  While RBANS and CWIT IV assess different 
neurocognitive elements, they may suggest that after a mTBI event there may 
be detectable changes in brain function in the mTBI group whether fully 
recovered or not.  This has been found by Kraus et al. (158) with a study of 25 
male college athletes who had suffered a concussive event compared to a 
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control group of 25 male college athletes who had not.  They measured neural 
responses to speech and found that the mTBI group had smaller responses to 
speech than controls.  The authors suggest that this adds weight to evidence 
that a single concussive event can cause neuronal damage even though there is 
an absence of PCS symptoms (158).  This is important in advancing one step 
further in our understanding of Chronic Trauma Encephalopathy (CTE).  As a 
disease there is much uncertainty around whether this condition is a result of 
one or several mTBI events, or even accumulation of sub-concussive events (9).  
Could the neurocognitive tests used in this study and MRI findings serve as a 
predictor of this condition also?  The next step would be to reanalyze our data 
with a single mTBI group and compare neurocognitive outcomes and MRI 
findings with a group of healthy controls who have also undergone 
neurocognitive testing.  Unfortunately, our healthy control group did not 
undergo the neurocognitive testing and so this next step cannot be performed 
in this study.  To build on the results of this study I suggest a prospective 
longitudinal study with a mTBI group and normal controls using the 
neurocognitive controls and serial MRI imaging over time.   
 
7.5 	CP	as	a	control	for	PCS	
An important point of difference in this study was comparing the CP group to 
the PCS group in order to compare findings with another group experiencing 
symptoms who have not had a mTBI.  CP has many similarities with PCS, both 
with the heterogeneity of definitions and the reliance on clinical factors for 
diagnosis.  The uncertain pathophysiology, and the way in which only a small 
percentage of acute pain (or mTBI) patients go on and develop CP (or PCS) 
symptoms.  The baseline clinical features, namely time course and psychosocial 
factors involved in the development of each condition are also comparable.  
PCS and CP also share symptoms, baseline pre-morbid psychological 
conditions, and personality traits that can affect the development of chronicity 
in each condition.  Studies with direct comparison between PCS and CP show 
similar levels of self-reported symptoms across physical, cognitive and somatic 
domains (96)(63)(61).  This is reinforced by the similarities in the demographic 
characteristics between the PCS group and the CP group, with no statistically 
significant differences between HADS A or HADS D and the RPQ scores.  The 
PCS and CP groups approached but did not reach significance with p=0.058 
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with the PCS group having marginally higher RPQ scores than the CP group.  
By carefully matching both groups it has allowed the investigation of brain 
changes as a consequence of having a mTBI, rather than as a consequence of 
similar symptomology.  Does MRI have a role to investigate the brain changes 
associated with chronic pain and perhaps compared to PCS to show similarities 
between the two to aid understanding of the pathophysiology of both 
conditions?  It was for these reasons that CP was used as another control group 
in this thesis. 
 
The interesting outcome in this study was the significant structural and DTI 
findings in the CP group compared to all other groups, and no significant 
findings in the PCS group compared to controls in either modality.  Initially the 
idea was to use CP as an ‘active control group’ to compare against the PCS 
group, as given the cross-over of symptoms, treatment, etc. it was felt that this 
may provide a more appropriate model to investigate outcomes in TBI.  
Interestingly, our results support other literature in that the CP group have 
evidence of an organic disease process.  Perhaps it is fair to say that PCS and 
CP are not as similar as I initially thought and that the pathophysiology of each 
is in fact dissimilar.  Taken to the extreme, based on the findings here, perhaps 
PCS is not a disease but a chronic psychosocial condition that develops in 
individuals with at risk baseline characteristics and no observable 
microstructural brain changes exist with the technology we have available at 
this time.  Again, with only this study it is not possible to make this 
assumption, but given the heterogeneity of the mTBI literature, the next stage 
to further clarify if any brain changes exist is research with the newer 
techniques such as HARDI and diffusion kurtosis by using a prospective long 
term study using these imaging techniques in series over time. 
 
Patients with chronic pain are usually on multiple medications.  The mTBI 
groups are unlikely to be on medications long term.  Hence it is a good 
question to consider if the medication the CP group are taking will influence 
these brain changes.  In the CP literature, this question has also not been 





In this study, I used both structural (grey matter volume and cortical thickness) 
and DTI techniques to investigate the brains of participants who had 
experienced a mTBI.  The objective was to identify potential brain differences 
associated with full or poor recovery post mTBI, to see whether differences 
existed with a group of participants with chronic pain and a group of healthy 
controls.  
 
No significant statistical voxelwise differences were found in grey matter 
volume between the PCS and the Non-PCS groups, or compared to the control 
groups.  There were also no significant differences in supratentorial cortical 
thickness between any of the groups.  
 
The PCS and non-PCS groups showed no significant differences in FA or MD 
relative to controls, nor were there differences between the PCS and non-PCS 
groups in FA or MD.  As with the current study, many previous studies report 
an absence of marked brain differences between mTBI patients and controls, or 
within mTBI.  However, this negative finding does not support the majority of 
published literature on the topic.  This may be explained by the heterogenicity 
of methodology, mTBI definition and timing of MRI scan relative to time after 
injury across the literature.  Perhaps a more accurate comparison would be 
between mTBI and another trauma group, such as orthopaedic trauma whom 
did not suffer mTBI as both groups having experienced the trauma event.  This 
method has been used in other published literature (134). 
 
The CP group compared with all other groups showed reduced grey matter 
volume in the cerebellum.  These findings were particularly localized to the 
inferior cerebellar peduncles, vermis and cerebellar tonsils, which supports 
existing literature suggesting the cerebellum has a significant role in integration 
and modulating pain pathways.  There were no differences in cortical thickness 
in the CP group. The CP group exhibited FA and MD differences in the 
cerebellar/brainstem changes of reduced grey matter volume also support 
findings in published literature that show the supratentorial anatomical areas 
and brainstem involved in the processing and modulation of pain.   
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Overall the heterogeneity of the literature-including clinical group definitions, 
scan protocols, time intervals and small sample sizes-help to frame my results 
within the larger field.  Lack of significant differences is not an uncommon 
finding.  In my hands, PCS and non-PCS were indistinguishable on T1-
weighted images, as well as DTI.  Not reaching an established clinical threshold 
makes drawing comparisons to my study difficult.  	
	
Newer techniques such as HARDI and diffusion kurtosis maybe the next step 
in future research in this topic.  Or a new study looking at MRI changes over 
time starting in the acute stage, just after time of injury, and continuing with 
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